{"content":"<li class=\"n-box-item date-title\" data-end=\"1526615999\" data-start=\"1526529600\" data-txt=\"Monday, December 23, 2019\">Thursday, May 17, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3357816\" data-ts=\"1526594281\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOOT\" target=\"_blank\">BOOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357816-boot-barnminus-3_6-7_2m-share-offering-said-to-come-23_50-24\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boot Barn -3.6% as 7.2M-share offering said to come at $23.50-$24</a></h4><ul>   <li>Boot Barn (NASDAQ:<a href='https://seekingalpha.com/symbol/BOOT' title='Boot Barn Holdings'>BOOT</a>) has <font color='red'>dropped 3.6%</font> in postmarket action after launching a <a href=\"https://seekingalpha.com/pr/17167709-boot-barn-holdings-inc-announces-launch-public-offering-selling-stockholders\" target=\"_blank\">7.21M-share public offering</a> for selling stockholders.</li>    <li>Those will go for $23.50-$24/share, a source tells Bloomberg -- about a 2-4% discount from close. Shares settled at $24.49 on Nasdaq today.</li>    <li>The stockholders include funds managed by Freeman Spogli &amp; Co., offering its entire stake of 7,021,771 shares, and some directors who are offering 190,042 shares.</li>    <li>J.P. Morgan Securities and Jefferies are underwriters for the offering.</li>    <li>The company isn't selling shares and won't receive proceeds.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3357816\" data-linked=\"Boot Barn -3.6% as 7.2M-share offering said to come at $23.50-$24\" data-tweet=\"$BOOT - Boot Barn -3.6% as 7.2M-share offering said to come at $23.50-$24 https://seekingalpha.com/news/3357816-boot-barnminus-3_6-7_2m-share-offering-said-to-come-23_50-24?source=tweet\" data-url=\"https://seekingalpha.com/news/3357816-boot-barnminus-3_6-7_2m-share-offering-said-to-come-23_50-24\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357814\" data-ts=\"1526593559\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRNA\" target=\"_blank\">DRNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357814-dicernaplus-1_7-hyperoxaluria-treatment-gets-orphan-status-from-fda\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dicerna +1.7% as hyperoxaluria treatment gets orphan status from FDA</a></h4><ul>   <li>Dicerna Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DRNA' title='Dicerna Pharmaceuticals, Inc.'>DRNA</a>) is <font color='green'>up 1.7%</font> in late trading after getting an <a href=\"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=635418\" target=\"_blank\">orphan drug status</a> designation for its treatment for primary hyperoxaluria.</li>    <li>The FDA granted the status to Dicerna's synthetic double-stranded RNA oligonucleotide conjugated to N-acetyl-D-galactosamine aminosugar residues on Tuesday.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3357814\" data-linked=\"Dicerna +1.7% as hyperoxaluria treatment gets orphan status from FDA\" data-tweet=\"$DRNA - Dicerna +1.7% as hyperoxaluria treatment gets orphan status from FDA https://seekingalpha.com/news/3357814-dicernaplus-1_7-hyperoxaluria-treatment-gets-orphan-status-from-fda?source=tweet\" data-url=\"https://seekingalpha.com/news/3357814-dicernaplus-1_7-hyperoxaluria-treatment-gets-orphan-status-from-fda\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357809\" data-ts=\"1526592912\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QTNT\" target=\"_blank\">QTNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357809-after-hours-gainers-losers-05-17-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (05/17/2018)</a></h4><ul>     <li><b>Top gainers:</b>&nbsp;<a href='https://seekingalpha.com/symbol/QTNT' title='Quotient Limited'>QTNT</a>&nbsp;<font color='green'>+12.1%</font>.&nbsp;<a href='https://seekingalpha.com/symbol/AFSI' title='AmTrust Financial Services, Inc.'>AFSI</a> <font color='green'>+6.1%</font>. <a href='https://seekingalpha.com/symbol/EIGR' title='Eiger BioPharmaceuticals, Inc.'>EIGR</a>&nbsp;<font color='green'>+3.5%</font>. <a href='https://seekingalpha.com/symbol/DRNA' title='Dicerna Pharmaceuticals, Inc.'>DRNA</a> <font color='green'>+3.0%</font>. <a href='https://seekingalpha.com/symbol/TIVO' title='TiVo Inc.'>TIVO</a>&nbsp;<font color='green'>+2.0%</font>.</li>     <li><strong>Top Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/JWN' title='Nordstrom Inc.'>JWN</a> <font color='red'>-6.4%</font>. <a href='https://seekingalpha.com/symbol/ARQL' title='ArQule, Inc.'>ARQL</a>&nbsp;<font color='red'>-6.3%</font>.&nbsp;&nbsp;<a href='https://seekingalpha.com/symbol/STKL' title='SunOpta, Inc.'>STKL</a>&nbsp;<font color='red'>-5.2%.&nbsp;</font><a href='https://seekingalpha.com/symbol/AMAT' title='Applied Materials, Inc.'>AMAT</a>&nbsp;<font color='red'>-4.7%</font>. <a href='https://seekingalpha.com/symbol/BOOT' title='Boot Barn Holdings'>BOOT</a>&nbsp;<font color='red'>-3.8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3357809\" data-linked=\"After Hours Gainers / Losers (05/17/2018)\" data-tweet=\"$QTNT $QTNT $AFSI - After Hours Gainers / Losers (05/17/2018) https://seekingalpha.com/news/3357809-after-hours-gainers-losers-05-17-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3357809-after-hours-gainers-losers-05-17-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357807\" data-ts=\"1526592268\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARQL\" target=\"_blank\">ARQL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357807-arquleminus-6_3-registers-10_6m-shares-for-selling-holders\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ArQule -6.3% as it registers 10.6M shares for selling holders</a></h4><ul>   <li>ArQule (NASDAQ:<a href='https://seekingalpha.com/symbol/ARQL' title='ArQule, Inc.'>ARQL</a>) is <font color='red'>6.3% lower</font> in postmarket trade after it <a href=\"https://seekingalpha.com/filing/4029537\" target=\"_blank\">filed a registration statement</a> for up to 10.629M shares for sale by certain stockholders.</li>    <li>The share total includes 2.259M shares issuable upon the exercise of outstanding warrants.</li>    <li>The selling stockholders are Ran Nussbaum's Pontifax Group, along with the Sphera Global Healthcare Master Fund and HFR HE Sphera Global Healthcare Master Trust.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3357807\" data-linked=\"ArQule -6.3% as it registers 10.6M shares for selling holders\" data-tweet=\"$ARQL - ArQule -6.3% as it registers 10.6M shares for selling holders https://seekingalpha.com/news/3357807-arquleminus-6_3-registers-10_6m-shares-for-selling-holders?source=tweet\" data-url=\"https://seekingalpha.com/news/3357807-arquleminus-6_3-registers-10_6m-shares-for-selling-holders\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357802\" data-ts=\"1526591349\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QTNT\" target=\"_blank\">QTNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357802-quotient-limited-mosaiq-microarray-starting-europe-trials\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Quotient Limited MosaiQ microarray starting Europe trials</a></h4><ul>   <li>Diagnostics firm Quotient Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/QTNT' title='Quotient Limited'>QTNT</a>) is <font color='green'>up 11.9%</font> after hours following word that its initial blood grouping MosaiQ microarray has finished a verification/validation phase, and has <a href=\"https://seekingalpha.com/pr/17167660-quotient-limited-reports-commencement-eu-blood-grouping-field-trial\" target=\"_blank\">started field trials in Europe</a>.</li>    <li>Results of previously disclosed V&amp;V results implied overall concordance of 99.8% for antigen typing on the MosaiQ platform.</li>    <li>The MosaiQ IH microarray antibody detection requirement is to be 95% concordant with predicate technology.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3357802\" data-linked=\"Quotient Limited MosaiQ microarray starting Europe trials\" data-tweet=\"$QTNT - Quotient Limited MosaiQ microarray starting Europe trials https://seekingalpha.com/news/3357802-quotient-limited-mosaiq-microarray-starting-europe-trials?source=tweet\" data-url=\"https://seekingalpha.com/news/3357802-quotient-limited-mosaiq-microarray-starting-europe-trials\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357792\" data-ts=\"1526589925\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VJET\" target=\"_blank\">VJET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357792-voxeljetplus-7_7-despite-q1-misses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Voxeljet +7.7% despite Q1 misses,</a></h4><ul><li>        Voxeljet (NYSE:<a href='https://seekingalpha.com/symbol/VJET' title='voxeljet AG'>VJET</a>) shares are&nbsp;<font color='green'>up 7.7%</font>&nbsp;aftermarket on Q1 results that missed EPS and revenue estimates with a 12% Y/Y revenue growth. Reaffirmed FY18 guidance has revenue from &euro;28M to &euro;30M with gross margin above 40%.</li><li>               Earnings call is scheduled for tomorrow morning at 8:30 AM Eastern with a webcast available <a href=\"https://event.webcasts.com/starthere.jsp?ei=1191083&amp;tp_key=35bcb63183\" target=\"_blank\">here</a>.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17167704-voxeljet-ag-reports-financial-results-first-quarter-ended-march-31-2018\" target=\"_blank\">Press release</a>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357779-voxeljet-ag-misses-0_03-misses-revenue\" target=\"_blank\">Voxeljet AG misses by &euro;0.03, misses on revenue</a> (May 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3357792\" data-linked=\"Voxeljet +7.7% despite Q1 misses,\" data-tweet=\"$VJET - Voxeljet +7.7% despite Q1 misses, https://seekingalpha.com/news/3357792-voxeljetplus-7_7-despite-q1-misses?source=tweet\" data-url=\"https://seekingalpha.com/news/3357792-voxeljetplus-7_7-despite-q1-misses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357791\" data-ts=\"1526589581\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TYHT\" target=\"_blank\">TYHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357791-shineco-reports-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shineco reports Q3 results</a></h4><ul><li>Shineco (NASDAQ:<a href='https://seekingalpha.com/symbol/TYHT' title='Shineco, Inc.'>TYHT</a>): Q3 EPS of $0.21</li><li>Revenue of $13.34M (+68.0% Y/Y)</li><li>Shares <font color='green'>+11.76%</font>.</li><li><a href='https://seekingalpha.com/pr/17167738-shineco-inc-reports-third-quarter-2018-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3357791\" data-linked=\"Shineco reports Q3 results\" data-tweet=\"$TYHT - Shineco reports Q3 results https://seekingalpha.com/news/3357791-shineco-reports-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3357791-shineco-reports-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:39 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357788\" data-ts=\"1526589170\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVAV\" target=\"_blank\">AVAV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357788-aerovironment-allegations-over-hyped-short-seller-stifel-analyst-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AeroVironment allegations &#39;over-hyped&#39; by short seller, Stifel analyst says</a></h4><ul>     <li>AeroVironment (NASDAQ:<a href='https://seekingalpha.com/symbol/AVAV' title='AeroVironment, Inc.'>AVAV</a>) reversed morning losses to finish with a hefty 5.6% gain after Stifel analyst Joseph  DeNardi said he believed a whistleblower lawsuit's allegations were \"<a href=\"https://thefly.com/thestreet/realmoney/index.php/AVAVid2733206/AVAV-AeroVironment-lawsuit-allegations-overhyped-by-shortseller-says-Stifel\" target=\"_blank\">over-hyped</a>\" as part of a <a href=\"https://seekingalpha.com/news/3357674-aerovironment-hit-report-alleged-cover-illegal-activity\" target=\"_blank\">negative report</a> from short seller Aurelius Capital.</li><li>While Aurelius claims the lawsuit involves a \"cover-up of illegal activity and dangerous conduct,\" DeNardi said the incident related to a switchblade being transported on a Delta flight and was reported to the government in detail.</li><li>Stifel maintains a Buy rating and $65 price target on the stock.</li></ul><div class=\"tiny-share-widget\" data-id=\"3357788\" data-linked=\"AeroVironment allegations &#39;over-hyped&#39; by short seller, Stifel analyst says\" data-tweet=\"$AVAV - AeroVironment allegations &#39;over-hyped&#39; by short seller, Stifel analyst says https://seekingalpha.com/news/3357788-aerovironment-allegations-over-hyped-short-seller-stifel-analyst-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3357788-aerovironment-allegations-over-hyped-short-seller-stifel-analyst-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357782\" data-ts=\"1526588642\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AFSI\" target=\"_blank\">AFSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357782-amtrust-up-nearly-7-icahn-discloses-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AmTrust up nearly 7% as Icahn discloses stake</a></h4><ul><li>Carl Icahn <a href=\"https://seekingalpha.com/filing/4029221\" target=\"_blank\">discloses</a> a 9.4% stake in AmTrust (NASDAQ:<a href='https://seekingalpha.com/symbol/AFSI' title='AmTrust Financial Services, Inc.'>AFSI</a>). In the filing, Icahn says he's opposed to the going-private deal at $13.50 per share.</li><li><a href='https://seekingalpha.com/symbol/AFSI' title='AmTrust Financial Services, Inc.'>AFSI</a>&nbsp;<font color='green'>+6.85%</font>&nbsp;after hours to $14.35.</li><li><a href=\"http://carlicahn.com/open-letter-to-board-of-amtrust-financial/\" target=\"_blank\">Letter to the board:</a> \"The Zyskind/Karfunkel families, with the help of the 'independent' Special Committee of the Board, are blatantly taking advantage of AmTrust&rsquo;s minority shareholders.\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3335567-amtrust-agrees-buyout-13_50-per-share\" target=\"_blank\">AmTrust agrees to buyout at $13.50 per share</a> (March 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3357782\" data-linked=\"AmTrust up nearly 7% as Icahn discloses stake\" data-tweet=\"$AFSI - AmTrust up nearly 7% as Icahn discloses stake https://seekingalpha.com/news/3357782-amtrust-up-nearly-7-icahn-discloses-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3357782-amtrust-up-nearly-7-icahn-discloses-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357781\" data-ts=\"1526588631\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMAT\" target=\"_blank\">AMAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357781-applied-materialsminus-2-on-q2-beats-mixed-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Applied Materials -2% on Q2 beats, mixed guidance</a></h4><ul><li>        Applied Materials (NASDAQ:<a href='https://seekingalpha.com/symbol/AMAT' title='Applied Materials, Inc.'>AMAT</a>)&nbsp;<font color='red'>drops 2%</font>&nbsp;aftermarket on Q2 results that beat EPS and revenue results with a 29% Y/Y revenue growth. Q3 guidance has downside revenue of $4.33B to $4.53B (consensus: $4.54B) and in-line EPS of $1.13 to $1.21 (consensus: $1.16).</li><li>               Key metrics: Non-GAAP gross margin, 46.7% (+0.4 pts); operating margin, 30.2% (+2.4 pts); cash from operations, $611M; capital allocation, $2.6B; operating expenses, &nbsp;$763M; cash and equivalents, $4.87B.&nbsp;</li><li>               Segment performance: Semiconductor Systems, $3B (+25% Y/Y); Applied Global Services, $943M (+30%); Display and Adjacent Markets, &nbsp;$600M (+53%).&nbsp;</li><li>                  Earnings call is scheduled for 4:30 PM Eastern with a webcast available <a href=\"http://www.appliedmaterials.com/\" target=\"_blank\">here</a>.    </li><li>               <a href=\"https://seekingalpha.com/pr/17167634-applied-materials-delivers-strong-year-year-growth-quarterly-revenue-earnings-per-share\" target=\"_blank\">Press release</a>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357761-applied-materials-beats-0_08-beats-revenue\" target=\"_blank\">Applied Materials beats by $0.08, beats on revenue</a> (May 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3357781\" data-linked=\"Applied Materials -2% on Q2 beats, mixed guidance\" data-tweet=\"$AMAT - Applied Materials -2% on Q2 beats, mixed guidance https://seekingalpha.com/news/3357781-applied-materialsminus-2-on-q2-beats-mixed-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3357781-applied-materialsminus-2-on-q2-beats-mixed-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>49&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357780\" data-ts=\"1526588443\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JWN\" target=\"_blank\">JWN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357780-nordstrom-lower-after-sales-guidance-arrives-light\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nordstrom lower after sales guidance arrives light</a></h4><ul><li>Nordstrom (NYSE:<a href='https://seekingalpha.com/symbol/JWN' title='Nordstrom Inc.'>JWN</a>) reports comparable sales rose 0.6% in <a href=\"https://seekingalpha.com/pr/17167666-nordstrom-reports-first-quarter-2018-earnings\" target=\"_blank\">Q1</a> vs. +1.0% consensus estimate.</li><li>Comparable sales were up 0.7% at full-price stores and 0.4% at off-price outlets.</li><li>Digital sales rose 18% Y/Y to carve out 29% of all sales, compared to 25% a year ago.</li><li>Gross profit fell 21 bps to 34.1% of sales as higher occupancy costs nipped.</li><li>SG&amp;A expenses were up 32 bps to 32.3% of sales.</li><li>EBIT came in at $153M or 4.4% of sales vs. $151M and 4.6% of sales a year ago.</li><li>Nordstom ended the quarter with 373 stores vs. 353 stores a year ago, led by a net gain of 16 Nordstrom Rack stores.</li><li>The company reiterates full-year revenue guidance of $15.2B to $15.4B vs. $15.64B consensus. The forecast for EBIT is trimmed just slightly to $885M to $940M from $895M to $940M and $907M consensus.</li><li>Shares of Nordstrom are&nbsp;<font color='red'>down 5.16%</font>&nbsp;in AH trading to drop back below $50.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357764-nordstrom-beats-0_07-beats-revenue\" target=\"_blank\">Nordstrom beats by $0.07, beats on revenue</a> (May 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3357780\" data-linked=\"Nordstrom lower after sales guidance arrives light\" data-tweet=\"$JWN - Nordstrom lower after sales guidance arrives light https://seekingalpha.com/news/3357780-nordstrom-lower-after-sales-guidance-arrives-light?source=tweet\" data-url=\"https://seekingalpha.com/news/3357780-nordstrom-lower-after-sales-guidance-arrives-light\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357759\" data-ts=\"1526587128\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JE\" target=\"_blank\">JE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357759-just-energyminus-7-q1-ffo-ebitda-decline\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Just Energy -7% as Q1 FFO, EBITDA both decline</a></h4><ul>     <li>Just Energy (<a href='https://seekingalpha.com/symbol/JE' title='Just Energy Group, Inc.'>JE</a> <font color='red'>-6.8%</font>) sinks to a 52-week low following <a href=\"https://seekingalpha.com/news/3357459-just-energy-misses-revenue\" target=\"_blank\">Q4 results</a>, as base FFO fell 11% Y/Y to $25.5M and base EBITDA fell 8% Y/Y to $69M.</li>     <li>JE cites strategic sales growth initiative investments, abnormal weather-driven supply cost increases and non-recurring severance costs for the lower Y/Y results.</li>     <li>JE provides FY 2019 base EBITDA guidance of $200M-$220M including the implementation of IFRS 15, ~10% Y/Y growth at the midpoint; FY 2018 base EBITDA would have been ~$188M when adjusted for IFRS 15.</li>     <li>\"Moving forward, we&rsquo;re committed to executing a strategic shift from a retail energy provider to a consumer company. As a part of our transformation objectives, our stakeholders can expect Just Energy to take the necessary measures to remove the volatility and improve the transparency in our results,\" the company says.</li></ul><div class=\"tiny-share-widget\" data-id=\"3357759\" data-linked=\"Just Energy -7% as Q1 FFO, EBITDA both decline\" data-tweet=\"$JE - Just Energy -7% as Q1 FFO, EBITDA both decline https://seekingalpha.com/news/3357759-just-energyminus-7-q1-ffo-ebitda-decline?source=tweet\" data-url=\"https://seekingalpha.com/news/3357759-just-energyminus-7-q1-ffo-ebitda-decline\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357757\" data-ts=\"1526586079\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SQ\" target=\"_blank\">SQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357757-square-tracks-lower-paypal-stalking-izettle\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Square tracks lower with PayPal stalking iZettle</a></h4><ul><li>Shares of Square (NYSE:<a href='https://seekingalpha.com/symbol/SQ' title='Square, Inc.'>SQ</a>) are&nbsp;<font color='red'>down 2.6%</font>&nbsp;after Sky News tips that PayPal may be acquiring iZettle.</li><li>Square is off its session low of $54.60.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357742-paypal-said-pursuing-izettle\" target=\"_blank\">PayPal said to be pursuing iZettle</a> (May 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3357757\" data-linked=\"Square tracks lower with PayPal stalking iZettle\" data-tweet=\"$SQ - Square tracks lower with PayPal stalking iZettle https://seekingalpha.com/news/3357757-square-tracks-lower-paypal-stalking-izettle?source=tweet\" data-url=\"https://seekingalpha.com/news/3357757-square-tracks-lower-paypal-stalking-izettle\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357752\" data-ts=\"1526583988\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVE\" target=\"_blank\">CVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357752-cenovus-energyplus-3-bmo-upgrades-citing-rising-cash-flow-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cenovus Energy +3% as BMO upgrades, citing rising cash flow outlook</a></h4><ul>     <li>Cenovus Energy (<a href='https://seekingalpha.com/symbol/CVE' title='Cenovus Energy, Inc.'>CVE</a> <font color='green'>+2.9%</font>) is sharply higher after BMO&nbsp;Capital <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/05/11733935/bmo-upgrades-cenovus-amid-stronger-oil-prices\" target=\"_blank\">upgrades shares to Outperform</a> from Market Perform with a $17 price target, raised from $15, as stronger oil prices help repair the company's balance sheet, especially as \"the low oil price hedges roll off\" during the remainder of 2018.</li>     <li>BMO believes \"rising free cash flow and a deleveraged balance sheet could support a positive re-rating of Cenovus's valuation multiples,\" and the firm raises its 2018 cash flow/share forecast to $1.66 from $1.65 and its 2019 estimate to $2.91 from $2.89.</li>     <li>Helped by the lower-priced hedges beginning to dissipate, as well as higher production, the firm thinks CVE likely will generate $5.8B in surplus cash flow over the 2018-22 period.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3357752\" data-linked=\"Cenovus Energy +3% as BMO upgrades, citing rising cash flow outlook\" data-tweet=\"$CVE - Cenovus Energy +3% as BMO upgrades, citing rising cash flow outlook https://seekingalpha.com/news/3357752-cenovus-energyplus-3-bmo-upgrades-citing-rising-cash-flow-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3357752-cenovus-energyplus-3-bmo-upgrades-citing-rising-cash-flow-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357749\" data-ts=\"1526583340\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPSH\" target=\"_blank\">CPSH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357749-technology-top-5-gainers-losers-of-2_55-pm-05-17-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 2.55 PM (05/17/2018)</a></h4><ul>     <li><strong>Gainers:</strong> <a href='https://seekingalpha.com/symbol/CPSH' title='CPS Technologies Corp.'>CPSH</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/BBOX' title='Black Box Corporation'>BBOX</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/PCYG' title='Park City Group, Inc.'>PCYG</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/RVLT' title='Revolution Lighting Technologies, Inc.'>RVLT</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/ISNS' title='Image Sensing Systems, Inc.'>ISNS</a> <font color='green'>+7%</font>.</li>      <li><strong>Losers:</strong> <a href='https://seekingalpha.com/symbol/KEM' title='KEMET Corp.'>KEM</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/HEAR' title='Turtle Beach Corporation'>HEAR</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/NIHD' title='NII Holdings, Inc.'>NIHD</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/NTES' title='NetEase, Inc'>NTES</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/BLIN' title='Bridgeline Digital, Inc.'>BLIN</a> <font color='red'>-6%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3357749\" data-linked=\"Technology - Top 5 Gainers / Losers as of 2.55 PM (05/17/2018)\" data-tweet=\"$CPSH $CPSH $BBOX - Technology - Top 5 Gainers / Losers as of 2.55 PM (05/17/2018) https://seekingalpha.com/news/3357749-technology-top-5-gainers-losers-of-2_55-pm-05-17-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3357749-technology-top-5-gainers-losers-of-2_55-pm-05-17-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357747\" data-ts=\"1526583122\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ITUB\" target=\"_blank\">ITUB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357747-brazil-banks-fall-after-central-bank-keeps-interest-rate-unchanged\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brazil banks fall after central bank keeps interest rate unchanged</a></h4><ul><li>Itau Unibanco Holding (<a href='https://seekingalpha.com/symbol/ITUB' title='Itau Unibanco Holding S.A.'>ITUB</a> <font color='red'>-4.9%</font>),Banco Santander Brasil (<a href='https://seekingalpha.com/symbol/BSBR' title='Banco Santander &#40;Brasil&#41; S.A.'>BSBR</a> <font color='red'>-2.4%</font>), and Banco Bradesco (<a href='https://seekingalpha.com/symbol/BBD' title='Banco Bradesco, S.A.'>BBD</a> <font color='red'>-4.3%</font>) all slid after Brazil's central bank unexpectedly kept its benchmark Selic rate unchanged at 6.50%.</li><li>The bank's monetary policy committee says inflation developments remain favorable, \"with various measures of underlying inflation running still at low levels,\" the bank said in a <a href=\"http://www.bcb.gov.br/en/#!/c/news/1850\" target=\"_blank\">statement</a>.</li><li>It expects 2018 inflation at about 3.5%, rising to 4.0% in 2019 and 2020.</li><li>The committee says its scenario assumes a path for policy interest rate that ends this year at 6.5% p.a., and 2019 at 8.0% p.a.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3356757-bloomberg-investors-brazil-turn-bearish-bofa-ml-survey-finds\" target=\"_blank\">Bloomberg: Investors in Brazil turn bearish, BofA ML survey finds</a> (May 15)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/EWZ' title='iShares MSCI Brazil Capped ETF'>EWZ</a>, <a href='https://seekingalpha.com/symbol/BRZU' title='Direxion Daily Brazil Bull 3x Shares ETF'>BRZU</a>, <a href='https://seekingalpha.com/symbol/BZQ' title='ProShares UltraShort MSCI Brazil Capped ETF'>BZQ</a>, <a href='https://seekingalpha.com/symbol/BZF' title='WisdomTree Brazilian Real ETF'>BZF</a>, <a href='https://seekingalpha.com/symbol/UBR' title='ProShares Ultra MSCI Brazil Capped ETF'>UBR</a>, <a href='https://seekingalpha.com/symbol/DBBR' title='Deutsche X-trackers MSCI Brazil Hedged Equity ETF'>DBBR</a>, <a href='https://seekingalpha.com/symbol/FBZ' title='First Trust Brazil AlphaDEX ETF'>FBZ</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3357747\" data-linked=\"Brazil banks fall after central bank keeps interest rate unchanged\" data-tweet=\"$ITUB $ITUB $BSBR - Brazil banks fall after central bank keeps interest rate unchanged https://seekingalpha.com/news/3357747-brazil-banks-fall-after-central-bank-keeps-interest-rate-unchanged?source=tweet\" data-url=\"https://seekingalpha.com/news/3357747-brazil-banks-fall-after-central-bank-keeps-interest-rate-unchanged\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357746\" data-ts=\"1526582950\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSCO\" target=\"_blank\">CSCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357746-baird-still-bullish-on-cisco-after-solid-q3-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baird still bullish on Cisco after &#39;solid&#39; Q3 report</a></h4><ul>   <li>Investors may not like the guidance in Cisco's (NASDAQ:<a href='https://seekingalpha.com/symbol/CSCO' title='Cisco Systems, Inc.'>CSCO</a>) <a href=\"https://seekingalpha.com/news/3357425-cisco-minus-3_2-percent-largely-line-q3-earnings\" target=\"_blank\">Q3 earnings report</a> -- shares are <font color='red'>3.5% lower</font> and hit their lowest point in a month -- but Baird's Jayson Noland is sticking with bullishness.</li>    <li>The <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/05/11735174/take-advantage-of-ciscos-sell-off-baird-says\" target=\"_blank\">report was \"solid\"</a> and reinforced a view that the company's \"increasingly well positioned\" for differentiation, Noland writes.</li>    <li>He has an Outperform rating and reiterates a $51 price target, now representing 17% upside.</li>    <li><a href=\"https://seekingalpha.com/article/4175085-cisco-systems-inc-2018-q3-results-earnings-call-slides\" target=\"_blank\">Earnings call slides</a></li>    <li><a href=\"https://seekingalpha.com/article/4174879-ciscos-csco-ceo-chuck-robbins-q1-2018-results-earnings-call-transcript\" target=\"_blank\">Earnings call transcript</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3357746\" data-linked=\"Baird still bullish on Cisco after &#39;solid&#39; Q3 report\" data-tweet=\"$CSCO - Baird still bullish on Cisco after &#39;solid&#39; Q3 report https://seekingalpha.com/news/3357746-baird-still-bullish-on-cisco-after-solid-q3-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3357746-baird-still-bullish-on-cisco-after-solid-q3-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357745\" data-ts=\"1526582827\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INTC\" target=\"_blank\">INTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357745-intels-self-driving-cars-testing-in-jerusalem\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intel&#39;s self-driving cars testing in Jerusalem</a></h4><ul><li>        Intel (NASDAQ:<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a>) and its Mobileye subsidiary have started <a href=\"https://techcrunch.com/2018/05/17/intel-starts-testing-self-driving-cars-in-jerusalem/?utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+Techcrunch+%28TechCrunch%29\" target=\"_blank\">testing self-driving vehicles</a> in Jerusalem.</li><li>               The fleet includes 100 cars, and each has 12 cameras for a 360-degree view. Eight of the cameras are for long-range viewing and four for parking. The companies will add a layer of LIDAR and radar in the next few weeks.&nbsp;</li><li>               The company plans to deploy the fleet in the US and other regions in the &ldquo;coming months.&rdquo;&nbsp;</li><li>               Intel hopes to have self-driving vehicles on the road by 2021 in partnership with vehicle manufacturers.&nbsp;&nbsp;</li><li>Intel shares are&nbsp;<font color='green'>up 0.2%</font>&nbsp;to $54.74.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357495-big-self-driving-car-deal-mobileye\" target=\"_blank\">Big self-driving car deal for Mobileye</a> (May 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3357745\" data-linked=\"Intel&#39;s self-driving cars testing in Jerusalem\" data-tweet=\"$INTC - Intel&#39;s self-driving cars testing in Jerusalem https://seekingalpha.com/news/3357745-intels-self-driving-cars-testing-in-jerusalem?source=tweet\" data-url=\"https://seekingalpha.com/news/3357745-intels-self-driving-cars-testing-in-jerusalem\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357741\" data-ts=\"1526581745\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MLNX\" target=\"_blank\">MLNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357741-benchmark-upgrades-mellanox-after-guidance-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Benchmark upgrades Mellanox after guidance update</a></h4><ul><li>        Benchmark raises its Mellanox Tech (NASDAQ:<a href='https://seekingalpha.com/symbol/MLNX' title='Mellanox Technologies, Ltd.'>MLNX</a>) price target from $95 to $100 after today&rsquo;s guidance update.</li><li>               Source: Briefing.com.&nbsp;</li><li>               Mellanox shares are&nbsp;<font color='green'>up 3.1%</font>&nbsp;to $87.55.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357608-mellanox-tech-plus-5_2-percent-raised-q2-fy-guidance\" target=\"_blank\">Mellanox Tech +5.2% on raised Q2, FY guidance</a> (May 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3357741\" data-linked=\"Benchmark upgrades Mellanox after guidance update\" data-tweet=\"$MLNX - Benchmark upgrades Mellanox after guidance update https://seekingalpha.com/news/3357741-benchmark-upgrades-mellanox-after-guidance-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3357741-benchmark-upgrades-mellanox-after-guidance-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357739\" data-ts=\"1526580827\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JACK\" target=\"_blank\">JACK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357739-post-earnings-slump-for-jack-in-box\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Post-earnings slump for Jack in the Box</a></h4><ul><li>Jack in the Box (NASDAQ:<a href='https://seekingalpha.com/symbol/JACK' title='Jack In The Box Inc.'>JACK</a>) is&nbsp;<font color='red'>down 8.03%</font>&nbsp;after the company reports disappointing earnings and pushes off issuing long-term guidance until August as the post-Qdoba arrangements become clearer.</li><li>The restaurant operator says it has engaged an outside firm to help it identify cost-savings opportunities and analyzing new financing structures.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357419-comparable-sales-miss-jack-box\" target=\"_blank\">Comparable sales miss at Jack in the Box</a> (May 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3357739\" data-linked=\"Post-earnings slump for Jack in the Box\" data-tweet=\"$JACK - Post-earnings slump for Jack in the Box https://seekingalpha.com/news/3357739-post-earnings-slump-for-jack-in-box?source=tweet\" data-url=\"https://seekingalpha.com/news/3357739-post-earnings-slump-for-jack-in-box\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357738\" data-ts=\"1526580710\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XNET\" target=\"_blank\">XNET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357738-xunlei-unveils-products-for-blockchain-ecosystem\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xunlei unveils products for &#39;blockchain ecosystem&#39;</a></h4><ul>   <li>Xunlei Limited (<a href=\"http://seekingalpha.com/symbol/XNET\" target=\"_blank\">XNET</a> <font color='red'>-1.9%</font>) has announced developments in <a href=\"https://seekingalpha.com/pr/17166661-xunlei-launches-new-products-build-blockchain-ecosystem\" target=\"_blank\">blockchain infrastructure</a> it says are products to build a blockchain ecosystem.</li>    <li>StellarCloud is a shared platform designed to extend its existing content delivery network services to Infrastructure as a Service; it's intended to help companies in their transition to cloud services.</li>    <li>Coinciding with that announcement, it said iQiyi (<a href=\"http://seekingalpha.com/symbol/IQ\" target=\"_blank\">IQ</a> <font color='red'>-1.1%</font>) had joined in a strategic cooperation deal regarding StellarCloud.</li>    <li>Meanwhile, Xunlei says ThunderChain is high-performance blockchain infrastructure that can hit more than a million transactions per second.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3357738\" data-linked=\"Xunlei unveils products for &#39;blockchain ecosystem&#39;\" data-tweet=\"$XNET $XNET $IQ - Xunlei unveils products for &#39;blockchain ecosystem&#39; https://seekingalpha.com/news/3357738-xunlei-unveils-products-for-blockchain-ecosystem?source=tweet\" data-url=\"https://seekingalpha.com/news/3357738-xunlei-unveils-products-for-blockchain-ecosystem\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357735\" data-ts=\"1526580285\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357735-pareteum-in-3m-three-year-deal-security-service-provider\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pareteum in $3M, three-year deal with security service provider</a></h4><ul>   <li>Pareteum's (<a href=\"http://seekingalpha.com/symbol/TEUM\" target=\"_blank\">TEUM</a> <font color='red'>-1.8%</font>) latest contract win is a <a href=\"https://seekingalpha.com/pr/17166938-pareteum-adds-3-million-global-cloud-services-contract\" target=\"_blank\">$3M cloud contract</a> with an established UK-based enterprise.</li>    <li>The contract for Pareteum's Global Cloud Services Platform is a three-year deal, set with a customr who provides global security services (including home, fire and security monitoring) in more than 90 countries, along with employment screening, facilities management and enhanced tactical operations.</li>    <li>Pareteum will get monthly revenue for each connected device; the customer has more than 30,000 subscribers.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3357735\" data-linked=\"Pareteum in $3M, three-year deal with security service provider\" data-tweet=\"$TEUM - Pareteum in $3M, three-year deal with security service provider https://seekingalpha.com/news/3357735-pareteum-in-3m-three-year-deal-security-service-provider?source=tweet\" data-url=\"https://seekingalpha.com/news/3357735-pareteum-in-3m-three-year-deal-security-service-provider\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357731\" data-ts=\"1526580008\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGY\" target=\"_blank\">EGY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357731-energy-materials-top-5-gainers-losers-of-2-00-pm-05-17-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (05/17/2018)</a></h4><ul>     <li><strong>Gainers:</strong> <a href='https://seekingalpha.com/symbol/EGY' title='VAALCO Energy, Inc.'>EGY</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/UPL' title='Ultra Petroleum Corp.'>UPL</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/HK' title='Halcon Resources Corporation'>HK</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/ENSV' title='Enservco Corp.'>ENSV</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/TAT' title='TransAtlantic Petroleum Ltd.'>TAT</a> <font color='green'>+9%</font>.</li>     <li><strong>Losers:</strong> <a href='https://seekingalpha.com/symbol/LGCY' title='Legacy Reserves Inc'>LGCY</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/RKDA' title='Arcadia Biosciences'>RKDA</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SQM' title='Chemical & Mining Co. of Chile Inc.'>SQM</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/CAPL' title='CrossAmerica Partners LP'>CAPL</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/CGG-OLD' title='CGG'>CGG-OLD</a> <font color='red'>-6%</font>.</li>      &nbsp; </ul><div class=\"tiny-share-widget\" data-id=\"3357731\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (05/17/2018)\" data-tweet=\"$EGY $EGY $UPLC - Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (05/17/2018) https://seekingalpha.com/news/3357731-energy-materials-top-5-gainers-losers-of-2-00-pm-05-17-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3357731-energy-materials-top-5-gainers-losers-of-2-00-pm-05-17-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357726\" data-ts=\"1526577633\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMGN\" target=\"_blank\">IMGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357726-immunogens-mirventuximab-soravtansine-shows-positive-effect-in-early-stage-ovarian-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ImmunoGen&#39;s mirventuximab soravtansine shows positive effect in early-stage ovarian cancer study</a></h4><ul><li>ImmunoGen's (<a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a> <font color='red'>-2%</font>) antibody-drug conjugate &#40;ADC&#41; mirvetuximab soravtansine, in multiple combinations, showed a <a href=\"https://seekingalpha.com/pr/17166325-immunogen-announces-positive-findings-forward-ii-study-mirvetuximab-soravtansine-combination\" target=\"_blank\">treatment in benefit </a>in a Phase 1b clinical trial, FORWARD II, in patients with folate receptor alpha-positive ovarian cancer.</li><li>Data from a cohort of platinum-resistant patients who received mirvetuximab soravtansine + Roche's Avastin (bevacizumab) will be presented at ASCO in Chicago.</li><li>In 54 evaluable patients, the overall response rate &#40;ORR&#41; was 43% (n=23) with median progression-free survival &#40;PFS&#41; of 7.8 months. Patients received a median of three prior lines of therapy with 58% receiving prior treatment with Avastin.</li><li>In a subset of 23 evaluable patients with medium/high folate receptor alpha expression levels who received up to three prior lines of therapy, the ORR was 48% and median PFS was 9.9 months.</li><li>The confirmed ORR was 80% (n=8/10) in a subset of platinum-sensitive ovarian cancer patients treated with mirventuximab soravtansine + carboplatin.</li><li>Mirvetuximab soravtansine is an ADC that targets folate receptor alpha.</li><li>#ASCO18</li></ul><div class=\"tiny-share-widget\" data-id=\"3357726\" data-linked=\"ImmunoGen&#39;s mirventuximab soravtansine shows positive effect in early-stage ovarian cancer study\" data-tweet=\"$IMGN - ImmunoGen&#39;s mirventuximab soravtansine shows positive effect in early-stage ovarian cancer study https://seekingalpha.com/news/3357726-immunogens-mirventuximab-soravtansine-shows-positive-effect-in-early-stage-ovarian-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3357726-immunogens-mirventuximab-soravtansine-shows-positive-effect-in-early-stage-ovarian-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:20 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357722\" data-ts=\"1526576419\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CARV\" target=\"_blank\">CARV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357722-financials-top-gainers-losers-of-1-00-pm-05-17-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top Gainers / Losers as of 1:00 PM (05/17/2018)</a></h4><ul>     <li><strong>Gainers:</strong> <a href='https://seekingalpha.com/symbol/CARV' title='Carver Bancorp, Inc.'>CARV</a> <font color='green'>+82%</font>. <a href='https://seekingalpha.com/symbol/DS' title='Drive Shack Inc'>DS</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/OPHC' title='OptimumBank Holdings, Inc.'>OPHC</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/MFIN' title='Medallion Financial'>MFIN</a> <font color='green'>+7%</font>.</li>     <li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/FPAY' title='FlexShopper, Inc.'>FPAY</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a> <font color='red'>-11%</font>.</li>      &nbsp; </ul><div class=\"tiny-share-widget\" data-id=\"3357722\" data-linked=\"Financials - Top Gainers / Losers as of 1:00 PM (05/17/2018)\" data-tweet=\"$CARV $CARV $DS - Financials - Top Gainers / Losers as of 1:00 PM (05/17/2018) https://seekingalpha.com/news/3357722-financials-top-gainers-losers-of-1-00-pm-05-17-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3357722-financials-top-gainers-losers-of-1-00-pm-05-17-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357720\" data-ts=\"1526576337\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZAYO\" target=\"_blank\">ZAYO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357720-zayoplus-1_3-on-communications-infrastracture-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zayo +1.3% on communications infrastracture deal</a></h4><ul><li>        Zayo Group Holdings (NYSE:<a href='https://seekingalpha.com/symbol/ZAYO' title='Zayo Group'>ZAYO</a>) <a href=\"https://seekingalpha.com/pr/17166763-global-business-process-outsourcing-company-selects-zayo\" target=\"_blank\">announces</a> a global business process outsourcing company selected its integrated communications infrastructure. &nbsp;</li><li>        Zayo will provide over 80 cabinets of colocation space in a data center on the East Coast.</li><li>               Terms not disclosed but it is a multiyear deal.&nbsp;</li><li>               Zayo shares are&nbsp;<font color='green'>up 1.3%</font>&nbsp;to $34.01.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3357720\" data-linked=\"Zayo +1.3% on communications infrastracture deal\" data-tweet=\"$ZAYO - Zayo +1.3% on communications infrastracture deal https://seekingalpha.com/news/3357720-zayoplus-1_3-on-communications-infrastracture-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3357720-zayoplus-1_3-on-communications-infrastracture-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357718\" data-ts=\"1526575809\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNIT-OLD\" target=\"_blank\">CNIT-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357718-cnit-announces-1m-ad-terminal-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CNIT announces $1M ad terminal sales</a></h4><ul><li>        China Information Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/CNIT-OLD' title='China Information Technology'>CNIT-OLD</a>) <a href=\"https://seekingalpha.com/pr/17166770-cnit-receives-1-million-cloud-based-ad-terminal-order-taoping-alliance-s-new-members-qingyuan\" target=\"_blank\">announces</a> entering contracts to sell 3K cloud-based elevator ad terminals in office and residential buildings in Qingyuan.</li><li>               CNIT expects the contracts to generate sales and service revenue of about $1M. &nbsp;&nbsp;</li><li>               CNIT shares are&nbsp;<font color='red'>down 1.7%</font>&nbsp;to $1.74.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3357718\" data-linked=\"CNIT announces $1M ad terminal sales\" data-tweet=\"$CNIT-OLD - CNIT announces $1M ad terminal sales https://seekingalpha.com/news/3357718-cnit-announces-1m-ad-terminal-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3357718-cnit-announces-1m-ad-terminal-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:50 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357715\" data-ts=\"1526575786\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REGN\" target=\"_blank\">REGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357715-regeneron-and-sanofis-cemiplimab-shows-positive-effect-in-early-stage-lung-cancer-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Regeneron and Sanofi&#39;s cemiplimab shows positive effect in early-stage lung cancer study</a></h4><ul><li>Regeneron Pharmaceuticals (<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a> <font color='green'>+0.7%</font>) and development partner Sanofi (<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a> <font color='green'>+0.9%</font>) <a href=\"https://seekingalpha.com/pr/17166293-regeneron-sanofi-share-first-positive-clinical-data-cemiplimab-advanced-non-small-cell-lung\" target=\"_blank\">announce </a>positive preliminary data from a Phase 1 clinical trial assessing cemiplimab in advanced non-small cell lung cancer &#40;NSCLC&#41;. The results will be presented at ASCO in Chicago.</li><li>The overall response rate was 29% (n=6/21), all partial, and the disease control rate (responders + those with stable cancer) was 57% (n=12/21) as of the data cutoff date. Duration of response exceeded eight months in five of the six responders.</li><li>Regeneron's U.S. marketing application seeking approval for cemiplimab, a PD-1 inhibitor, for cutaneous squamous cell carcinoma is currently under FDA review with an action date of October 28.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3350168-regeneron-sanofis-cemiplimab-nabs-accelerated-review-u-s-type-skin-cancer\" target=\"_blank\">Regeneron and Sanofi's cemiplimab nabs accelerated review in U.S. for type of skin cancer</a> (April 30)</li><li>#ASCO18</li></ul><div class=\"tiny-share-widget\" data-id=\"3357715\" data-linked=\"Regeneron and Sanofi&#39;s cemiplimab shows positive effect in early-stage lung cancer study\" data-tweet=\"$REGN $REGN $SNY - Regeneron and Sanofi&#39;s cemiplimab shows positive effect in early-stage lung cancer study https://seekingalpha.com/news/3357715-regeneron-and-sanofis-cemiplimab-shows-positive-effect-in-early-stage-lung-cancer-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3357715-regeneron-and-sanofis-cemiplimab-shows-positive-effect-in-early-stage-lung-cancer-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357713\" data-ts=\"1526575376\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENS\" target=\"_blank\">ENS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357713-enersysplus-8-after-q1-beat-upside-earnings-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Enersys +8% after Q1 beat, upside earnings guidance</a></h4><ul>     <li>EnerSys (<a href='https://seekingalpha.com/symbol/ENS' title='EnerSys'>ENS</a> <font color='green'>+8%</font>) surges to its highest in 11 months after <a href=\"https://seekingalpha.com/news/3357428-enersys-beats-0_01-beats-revenue\" target=\"_blank\">Q4 earnings</a> and revenues edge analyst estimates as sales of premium products topped 40% of total company sales for the first time.</li>     <li>ENS issues upside guidance for Q1, seeing EPS of $1.15-$1.19 vs. $1.13 analyst consensus estimate, saying that while lead and other commodities continued to rise during most of Q4, the spot rate has since declined more than 10%, which should benefit results.</li>     <li>ENS also expects FY 2018 adjusted net earnings of $4.65/share, compared to prior year adjusted net earnings of $4.75, largely due to an unfavorable tax impact of $80.9M, or $1.88/share.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3357713\" data-linked=\"Enersys +8% after Q1 beat, upside earnings guidance\" data-tweet=\"$ENS - Enersys +8% after Q1 beat, upside earnings guidance https://seekingalpha.com/news/3357713-enersysplus-8-after-q1-beat-upside-earnings-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3357713-enersysplus-8-after-q1-beat-upside-earnings-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:42 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357712\" data-ts=\"1526575357\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EPAM\" target=\"_blank\">EPAM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357712-epam-systemsplus-1_7-on-target-increase-to-17-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EPAM Systems +1.7% on target increase to 17% upside</a></h4><ul><li>        Cowen <a href=\"https://www.streetinsider.com/Analyst+Comments/EPAM+Systems+%28EPAM%29+PT+Raised+to+%24145+at+Cowen%3B+Continues+to+Outperform+the+Industry/14206610.html\" target=\"_blank\">maintains</a> an Outperform rating on EPAM Systems (NYSE:<a href='https://seekingalpha.com/symbol/EPAM' title='EPAM Systems'>EPAM</a>) but raises the price target by $15 to $145.</li><li>               New target represents a 17% upside to yesterday&rsquo;s close.&nbsp;</li><li>               EPAM shares are&nbsp;<font color='green'>up 1.7% t</font>o $125.68.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3357712\" data-linked=\"EPAM Systems +1.7% on target increase to 17% upside\" data-tweet=\"$EPAM - EPAM Systems +1.7% on target increase to 17% upside https://seekingalpha.com/news/3357712-epam-systemsplus-1_7-on-target-increase-to-17-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3357712-epam-systemsplus-1_7-on-target-increase-to-17-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357711\" data-ts=\"1526575215\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CARV\" target=\"_blank\">CARV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357711-midday-gainers-losers-05-17-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (05/17/2018)</a></h4><ul>     <li><strong>Gainers:</strong> <a href='https://seekingalpha.com/symbol/CARV' title='Carver Bancorp, Inc.'>CARV</a> <font color='green'>+78%</font>. <a href='https://seekingalpha.com/symbol/CPSH' title='CPS Technologies Corp.'>CPSH</a> <font color='green'>+40%</font>. <a href='https://seekingalpha.com/symbol/EGY' title='VAALCO Energy, Inc.'>EGY</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/EIGR' title='Eiger BioPharmaceuticals, Inc.'>EIGR</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/BZUN' title='Baozun'>BZUN</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/BDSI' title='BioDelivery Sciences International, Inc.'>BDSI</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/RTTR' title='Ritter Pharmaceuticals'>RTTR</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/ESND' title='Essendant'>ESND</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/WWE' title='World Wrestling Entertainment, Inc.'>WWE</a> <font color='green'>+15%</font>.</li>      <li><strong>Losers:</strong> <a href='https://seekingalpha.com/symbol/JNCE' title='Jounce Therapeutics'>JNCE</a> <font color='red'>-33%</font>. <a href='https://seekingalpha.com/symbol/SNDX' title='Syndax Pharmaceuticals, Inc.'>SNDX</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/INSE' title='Inspired Entertainment, Inc.'>INSE</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/NIHD' title='NII Holdings, Inc.'>NIHD</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/DVAX' title='Dynavax Technologies Corporation'>DVAX</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/LGCY' title='Legacy Reserves Inc'>LGCY</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/LGCYO' title='Legacy Reserves LP Cum Red Perp Pfd Units Series B'>LGCYO</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/FPAY' title='FlexShopper, Inc.'>FPAY</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/KEM' title='KEMET Corp.'>KEM</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/JCP' title='J.C. Penney Company Inc.'>JCP</a> <font color='red'>-11%</font>.</li> &nbsp; </ul><div class=\"tiny-share-widget\" data-id=\"3357711\" data-linked=\"Midday Gainers / Losers (05/17/2018)\" data-tweet=\"$CARV $CARV $CPSH - Midday Gainers / Losers (05/17/2018) https://seekingalpha.com/news/3357711-midday-gainers-losers-05-17-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3357711-midday-gainers-losers-05-17-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357710\" data-ts=\"1526574888\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VHC\" target=\"_blank\">VHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357710-virnetxplus-3_2-on-reseller-agreement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VirnetX +3.2% on reseller agreement</a></h4><ul><li>        VirnetX (NYSEMKT:<a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a>) <a href=\"https://seekingalpha.com/pr/17167133-titan-commerce-signs-virnetx-sell-gabriel-secure-communications-secure-domain-names\" target=\"_blank\">announces</a> entering a non-exclusive reseller agreement with TITAN Commerce Continental Services, a German products and services retailer.</li><li>               The deal relates to VirnetX&rsquo;s Gabriel Collaboration Suite and Secure Domain Name technology.&nbsp;</li><li>               Financial terms not disclosed.&nbsp;</li><li>               VirnetX shares are&nbsp;<font color='green'>up 3.2%</font>&nbsp;to $3.20.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3357710\" data-linked=\"VirnetX +3.2% on reseller agreement\" data-tweet=\"$VHC - VirnetX +3.2% on reseller agreement https://seekingalpha.com/news/3357710-virnetxplus-3_2-on-reseller-agreement?source=tweet\" data-url=\"https://seekingalpha.com/news/3357710-virnetxplus-3_2-on-reseller-agreement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357709\" data-ts=\"1526574611\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESND\" target=\"_blank\">ESND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357709-consumer-top-5-gainers-losers-of-12-30-pm-05-17-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top 5 Gainers / Losers as of 12:30 PM (05/17/2018)</a></h4><ul>     <li><strong>Gainers</strong>: <a href='https://seekingalpha.com/symbol/ESND' title='Essendant'>ESND</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/STKL' title='SunOpta, Inc.'>STKL</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/ANFI' title='Amira Nature Foods'>ANFI</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/LFVN' title='LifeVantage Corporation'>LFVN</a> <font color='green'>+5%</font>.</li><li><strong>Losers:</strong> <a href='https://seekingalpha.com/symbol/FLO' title='Flowers Foods, Inc.'>FLO</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/TOUR' title='Tuniu Corporation'>TOUR</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/BRFS' title='BRF-Brasil Foods S.A.'>BRFS</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/REED' title='Reed&#39;s, Inc.'>REED</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3357709\" data-linked=\"Consumer - Top 5 Gainers / Losers as of 12:30 PM (05/17/2018)\" data-tweet=\"$ESND $ESND $STKL - Consumer - Top 5 Gainers / Losers as of 12:30 PM (05/17/2018) https://seekingalpha.com/news/3357709-consumer-top-5-gainers-losers-of-12-30-pm-05-17-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3357709-consumer-top-5-gainers-losers-of-12-30-pm-05-17-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357707\" data-ts=\"1526574511\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MFGP\" target=\"_blank\">MFGP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357707-analyst-says-buy-to-micro-focus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analyst says Buy to Micro Focus</a></h4><ul><li>        Canaccord Genuity <a href=\"https://www.streetinsider.com/Upgrades/Canaccord+Genuity+Upgrades+Micro+Focus+Intl+PLC+%28MFGP%29+to+Buy/14207770.html\" target=\"_blank\">upgrades</a> Micro Focus (NYSE:<a href='https://seekingalpha.com/symbol/MFGP' title='Micro Focus International plc ADR'>MFGP</a>) from Speculative Buy to Buy.</li><li>               Micro Focus shares are&nbsp;<font color='green'>up 0.6%</font>&nbsp;to $18.17.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3357707\" data-linked=\"Analyst says Buy to Micro Focus\" data-tweet=\"$MFGP - Analyst says Buy to Micro Focus https://seekingalpha.com/news/3357707-analyst-says-buy-to-micro-focus?source=tweet\" data-url=\"https://seekingalpha.com/news/3357707-analyst-says-buy-to-micro-focus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357706\" data-ts=\"1526574107\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LOXO\" target=\"_blank\">LOXO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357706-healthcare-top-5-gainers-losers-of-12-20-05-17-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 12:20 AM (05/17/2018)</a></h4><ul>     <li><strong>Gainers</strong>: <a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/RTTR' title='Ritter Pharmaceuticals'>RTTR</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/EIGR' title='Eiger BioPharmaceuticals, Inc.'>EIGR</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/BDSI' title='BioDelivery Sciences International, Inc.'>BDSI</a> <font color='green'>+15%</font>.</li><li><strong>Losers:</strong> <a href='https://seekingalpha.com/symbol/JNCE' title='Jounce Therapeutics'>JNCE</a> <font color='red'>-33%</font>. <a href='https://seekingalpha.com/symbol/SNDX' title='Syndax Pharmaceuticals, Inc.'>SNDX</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/DVAX' title='Dynavax Technologies Corporation'>DVAX</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/TORC' title='resTORbio, Inc.'>TORC</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/BPMC' title='Blueprint Medicines'>BPMC</a> <font color='red'>-10%</font>.</li> &nbsp; </ul><div class=\"tiny-share-widget\" data-id=\"3357706\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 12:20 AM (05/17/2018)\" data-tweet=\"$LOXO $LOXO $RTTR - Healthcare - Top 5 Gainers / Losers as of 12:20 AM (05/17/2018) https://seekingalpha.com/news/3357706-healthcare-top-5-gainers-losers-of-12-20-05-17-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3357706-healthcare-top-5-gainers-losers-of-12-20-05-17-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:21 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357704\" data-ts=\"1526573935\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPSH\" target=\"_blank\">CPSH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357704-cps-technologies-announces-29m-agreements\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CPS Technologies announces $29M agreements</a></h4><ul><li>        CPS Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/CPSH' title='CPS Technologies Corp.'>CPSH</a>) <a href=\"https://seekingalpha.com/pr/17167411-cps-technologies-corp-announces-29m-new-alsic-orders-key-customers\" target=\"_blank\">announces</a> receiving sourcing and pricing agreements with key customers for $29M over two years</li><li>               The agreements relate to the use of AISiC baseplates in traction and HEV/EV markets.&nbsp;</li><li>               CPS Tech shares are&nbsp;<font color='green'>up 19.9%</font>&nbsp;to $1.57.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3357704\" data-linked=\"CPS Technologies announces $29M agreements\" data-tweet=\"$CPSH - CPS Technologies announces $29M agreements https://seekingalpha.com/news/3357704-cps-technologies-announces-29m-agreements?source=tweet\" data-url=\"https://seekingalpha.com/news/3357704-cps-technologies-announces-29m-agreements\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357701\" data-ts=\"1526573073\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNQ\" target=\"_blank\">CNQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357701-canadian-naturalplus-2_5-on-plan-to-buy-back-up-to-5-of-shares-outstanding\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canadian Natural +2.5% on plan to buy back up to 5% of shares outstanding</a></h4><ul>     <li>Canadian Natural Resources (<a href='https://seekingalpha.com/symbol/CNQ' title='Canadian Natural Resources, Ltd.'>CNQ</a> <font color='green'>+2.5%</font>) is higher after announcing plans for a <a href=\"https://seekingalpha.com/pr/17166304-canadian-natural-resources-limited-announces-normal-course-issuer-bid\" target=\"_blank\">normal course issuer bid</a> for purchase for cancellation of as many as ~61.4M shares, or 5% of all outstanding common shares.</li>     <li>CNQ says it has acquired 702.7K shares for cancellation under its current normal course issuer bid, which authorized the repurchase of nearly 28M common shares.</li>     <li>CNQ cites returns to shareholders as a company priority, in addition to further strengthening its balance sheet, investing in exploration and development of its diverse asset base, and participating in acquisition  opportunities.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3357701\" data-linked=\"Canadian Natural +2.5% on plan to buy back up to 5% of shares outstanding\" data-tweet=\"$CNQ - Canadian Natural +2.5% on plan to buy back up to 5% of shares outstanding https://seekingalpha.com/news/3357701-canadian-naturalplus-2_5-on-plan-to-buy-back-up-to-5-of-shares-outstanding?source=tweet\" data-url=\"https://seekingalpha.com/news/3357701-canadian-naturalplus-2_5-on-plan-to-buy-back-up-to-5-of-shares-outstanding\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357697\" data-ts=\"1526572385\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBS\" target=\"_blank\">CBS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357697-cbsminus-6_2-judge-denies-restraining-order-in-re-merger-fight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CBS -6.2% as judge denies restraining order in re-merger fight</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/CBS' title='CBS Corporation'>CBS</a> is on the slide, <font color='red'>down 6.2%</font>, after the Redstone family wins a key court decision in their fight with the broadcaster over a potential re-merger with Viacom (<a href='https://seekingalpha.com/symbol/VIA' title='Viacom Inc.'>VIA</a> <font color='green'>+0.7%</font>, <a href='https://seekingalpha.com/symbol/VIAB' title='Viacom Inc.'>VIAB</a> <font color='red'>-0.2%</font>).</li>     <li>The court denied a CBS bid to stop National Amusements and Shari Redstone from interfering with today's CBS board meeting, saying the broadcaster failed to show irreparable harm.</li>     <li>A temporary restraining order that CBS sought was <a href=\"https://twitter.com/eriqgardner/status/997141052220887041\" target=\"_blank\">denied</a>, <i>THR's</i> Eriq Gardner reports.</li>     <li>That means Redstone can block a CBS&nbsp;board vote that would dilute NAI's voting power and thus its control of CBS.</li>   <li><b>Updated 12:04 p.m.:</b> It's not the last showdown of the day, as a <a href=\"https://twitter.com/CNBCnow/status/997144910347292673\" target=\"_blank\">CBS statement</a> says the board is meeting at 5 p.m. as scheduled and will consider declaring the dilutive dividend \"as is permitted under CBS' charter. This dividend would more closely align economic and voting interests of CBS stockholders without diluting the economic interests of any stockholder.\" NAI <a href=\"https://seekingalpha.com/news/3357410-judge-punts-decision-cbs-nai-feud-morning\" target=\"_blank\">rewrote CBS bylaws</a> yesterday to call for a board supermajority in such votes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3357697\" data-linked=\"CBS -6.2% as judge denies restraining order in re-merger fight\" data-tweet=\"$CBS $VIAC $VIA - CBS -6.2% as judge denies restraining order in re-merger fight https://seekingalpha.com/news/3357697-cbsminus-6_2-judge-denies-restraining-order-in-re-merger-fight?source=tweet\" data-url=\"https://seekingalpha.com/news/3357697-cbsminus-6_2-judge-denies-restraining-order-in-re-merger-fight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357695\" data-ts=\"1526572232\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NGG\" target=\"_blank\">NGG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357695-national-gridplus-3-full-year-yearly-profit-pops-24\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">National Grid +3% as full-year yearly profit pops 24%</a></h4><ul>     <li>National Grid (<a href='https://seekingalpha.com/symbol/NGG' title='National Grid plc'>NGG</a> <font color='green'>+3.3%</font>) is sharply higher after reporting a <a href=\"https://www.marketwatch.com/story/national-grid-yearly-profit-rises-24-2018-05-17\" target=\"_blank\">24% Y/Y increase</a> in its <a href=\"https://seekingalpha.com/news/3357556-national-grid-reports-fy-results\" target=\"_blank\">FY 2018 pretax profit</a> and expresses <a href=\"https://www.reuters.com/article/us-national-grid-results/national-grids-full-year-profits-rise-helped-by-u-s-business-idUSKCN1II0N4\" target=\"_blank\">optimism about its growth prospects</a>.</li>     <li>NGG says it expects growth in its business of at least 7% in the near term and at the top end of its 5%-7% guidance range for the medium term as the U.S. business should continue performing well while the U.K. business remains on track to outperform.</li>     <li>NGG says its pretax profit for the fiscal year ended March 31 totaled &euro;2.71B ($3.66B) vs. &euro;2.18B a year earlier, while FY 2018 revenues rose to &euro;15.25B compared with &euro;15.04B in FY 2017 and analyst consensus estimate of &euro;15.07B; net profit from continuing operations was &euro;2.06B vs. &euro;1.81B a year earlier and &euro;2.04B consensus.</li>     <li>Full-year profit from NGG's regulated business in the U.S., which contributes about half of the total, fell slightly to &euro;1.7B but edged analyst consensus of &euro;1.66B.</li></ul><div class=\"tiny-share-widget\" data-id=\"3357695\" data-linked=\"National Grid +3% as full-year yearly profit pops 24%\" data-tweet=\"$NGG - National Grid +3% as full-year yearly profit pops 24% https://seekingalpha.com/news/3357695-national-gridplus-3-full-year-yearly-profit-pops-24?source=tweet\" data-url=\"https://seekingalpha.com/news/3357695-national-gridplus-3-full-year-yearly-profit-pops-24\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357694\" data-ts=\"1526572225\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FARM\" target=\"_blank\">FARM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357694-farmer-brothers-seen-possible-cott-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Farmer Brothers seen as possible Cott target</a></h4><ul>  <li>Farmer Brothers (NASDAQ:<a href='https://seekingalpha.com/symbol/FARM' title='Farmer Brothers Company'>FARM</a>) is <font color='green'>up 4.3%</font> in what could be a delayed reaction to RBC analyst Nik Mondi's prediction that the company could be acquired by Cott (<a href='https://seekingalpha.com/symbol/COT' title='Cott Corporation'>COT</a> <font color='red'>-1.1%</font>) if shares fall off again.</li> <li>Shares of Farmer Brothers are down 17% YTD.</li><li>Sources: Bloomberg, Marketwatch</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3357694\" data-linked=\"Farmer Brothers seen as possible Cott target\" data-tweet=\"$FARM $FARM $COT - Farmer Brothers seen as possible Cott target https://seekingalpha.com/news/3357694-farmer-brothers-seen-possible-cott-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3357694-farmer-brothers-seen-possible-cott-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357693\" data-ts=\"1526572174\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTWO\" target=\"_blank\">TTWO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357693-take-two-rebounds-analysts-look-ahead-key-games\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Take-Two rebounds as analysts look ahead at key games</a></h4><ul>   <li>Take-Two Interactive (NASDAQ:<a href='https://seekingalpha.com/symbol/TTWO' title='Take-Two Interactive Software, Inc.'>TTWO</a>) has rebounded from last night's <a href=\"https://seekingalpha.com/news/3357439-take-two-resumes-5_5-percent-revenue-miss-low-guidance\" target=\"_blank\">post-earnings declines</a>, settling in for <font color='green'>2% gains</font> currently after hitting a 3.5-month high this morning.</li>    <li>The company guided low and missed on revenues, and a key release <i>(Borderlands 3)</i> was pushed off into the next fiscal year, but Jefferies is more focused on the high-profile release of <i>Red Dead Redemption 2</i> (coming this fall after its own delay).</li>    <li>\"It was a messy quarter with a lot of moving parts,\" analyst Timothy O'Shea says, with revenues likely dinged not only by rival game <i>Fortnite</i> but also by <i>NBA 2K</i> sales that were lighter than expected. Still, his bottom line is to own the stock</li>    <li>Baird's Colin Sebastian is largely of the same mind, looking past <i>Fortnite</i> competition to the <i>RDR2</i> release. Competition from <i>Fortnite</i> and <i>PlayerUnknown's Battlegrounds</i> still had its impact, though, given Take-Two's dependence on recurring revenues.</li>    <li>KeyBanc stayed Overweight as well, raising its price target to $152. A more cautious Cowen rates the stock Market Perform with a $96 target, with \"significant\" growth of its key franchises fully priced in already.</li>    <li>Big rivals were down in lockstep during last night's postmarket action, but they're higher alongside Take-Two today: <a href='https://seekingalpha.com/symbol/ATVI' title='Activision Blizzard, Inc'>ATVI</a> <font color='green'>+1.7%</font>; <a href='https://seekingalpha.com/symbol/EA' title='Electronic Arts Inc.'>EA</a> <font color='green'>+0.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3357693\" data-linked=\"Take-Two rebounds as analysts look ahead at key games\" data-tweet=\"$TTWO $TTWO $ATVI - Take-Two rebounds as analysts look ahead at key games https://seekingalpha.com/news/3357693-take-two-rebounds-analysts-look-ahead-key-games?source=tweet\" data-url=\"https://seekingalpha.com/news/3357693-take-two-rebounds-analysts-look-ahead-key-games\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357692\" data-ts=\"1526572152\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BZUN\" target=\"_blank\">BZUN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357692-baozunplus-18_6-on-q1-beats-16-y-y-revenue-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baozun +18.6% on Q1 beats, 16% Y/Y revenue growth</a></h4><ul><li>        Baozun (NASDAQ:<a href='https://seekingalpha.com/symbol/BZUN' title='Baozun'>BZUN</a>)&nbsp;<font color='green'>pops 18.6%</font>&nbsp;on Q1 results that beat EPS and revenue estimates with a 16% Y/Y revenue growth. Q2 guidance has services revenue growing over 50%Y/Y.</li><li>                  Key metrics: Services revenue, $73.5M (+50% Y/Y); operating margin, 5% (+0.8 pts); operating expenses, $142.3M; cash and equivalents, $113.1M.    </li><li>               <a href=\"https://seekingalpha.com/pr/17166504-baozun-announces-first-quarter-2018-unaudited-financial-results\" target=\"_blank\">Press release</a>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357505-baozun-beats-0_01-beats-revenue\" target=\"_blank\">Baozun beats by $0.01, beats on revenue</a> (May 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3357692\" data-linked=\"Baozun +18.6% on Q1 beats, 16% Y/Y revenue growth\" data-tweet=\"$BZUN - Baozun +18.6% on Q1 beats, 16% Y/Y revenue growth https://seekingalpha.com/news/3357692-baozunplus-18_6-on-q1-beats-16-y-y-revenue-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3357692-baozunplus-18_6-on-q1-beats-16-y-y-revenue-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>49&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357677\" data-ts=\"1526570684\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DLNG\" target=\"_blank\">DLNG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357677-dynagas-lng-partners-up-2-post-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dynagas LNG Partners up 2% post Q1 results</a></h4><ul><li>Dynagas LNG Partners (<a href='https://seekingalpha.com/symbol/DLNG' title='Dynagas LNG Partners LP'>DLNG</a> <font color='green'>+1.6%</font>) <a href=\"http://www.dynagaspartners.com/upload_press/dlng051618.pdf\" target=\"_blank\">reports Q1</a> revenue decrease of 13.3% Y/Y to&nbsp;$33.9M; this decrease was driven by the lower revenues earned on the Clean Energy.</li><li>Q1 overall margins: Operating income&nbsp;<font color='red'>declined 645 bps</font>&nbsp;to 49.5%; Adj. EBITDA&nbsp;<font color='red'>declined 185 bps</font>&nbsp;to 78.5%.</li><li>Distributable cash flow was $11.3M; cash &amp; equivalent of $61.4M (-9% Q/Q) &amp; available liquidity was $91.4M</li><li>Number of vessels were 6;&nbsp;Calendar &amp; Available days of 540;&nbsp;Vessel daily operating expenses was $11,741 (-5.6% Y/Y);&nbsp;Time Charter Equivalent of $61,635 (-13% Y/Y) &amp;&nbsp;Fleet Utilization of 100%.</li><li>The company declared cash dividend of $0.25 per share.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357415-dynagas-lng-partners-lp-beats-0_01-misses-revenue\" target=\"_blank\">Dynagas LNG Partners LP beats by $0.01, misses on revenue</a> (May 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3357677\" data-linked=\"Dynagas LNG Partners up 2% post Q1 results\" data-tweet=\"$DLNG - Dynagas LNG Partners up 2% post Q1 results https://seekingalpha.com/news/3357677-dynagas-lng-partners-up-2-post-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3357677-dynagas-lng-partners-up-2-post-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357684\" data-ts=\"1526570682\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TK\" target=\"_blank\">TK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357684-teekayminus-7-on-wider-expected-q1-loss-warning-on-tanker-rates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teekay -7% on wider than expected Q1 loss, warning on tanker rates</a></h4><ul>     <li>Teekay Corp. (<a href='https://seekingalpha.com/symbol/TK' title='Teekay Corporation'>TK</a> <font color='red'>-7.7%</font>) falls as much as 16% for its largest intraday drop since June 2017 after reporting a wider than expected <a href=\"https://seekingalpha.com/news/3357510-teekay-misses-0_11-beats-revenue\" target=\"_blank\">Q1 loss</a> and warning that its Teekay Tankers (<a href='https://seekingalpha.com/symbol/TNK' title='Teekay Tankers Ltd'>TNK</a> <font color='red'>-4.7%</font>) subsidiary may face weak tanker rates for most of this year.</li>     <li>&ldquo;While tanker rates are expected to remain weak  in the near-term, we are anticipating a gradual improvement in fleet  utilization and tanker rates from late-2018,\" TK CEO Kenneth Hvid says.</li>     <li>On Teekay LNG (<a href='https://seekingalpha.com/symbol/TGP' title='Teekay LNG Partners L.P.'>TGP</a> <font color='green'>+0.3%</font>), Hvid says the company \" is in the early innings of a multi-year cash flow ramp-up with an additional 11 LNG carriers and a regasification facility scheduled to start-up through early-2020.\"</li>     <li>On Teekay Offshore (<a href='https://seekingalpha.com/symbol/TOO' title='Teekay Offshore Partners L.P.'>TOO</a> <font color='green'>+3.3%</font>), \"We have now completed all our near-term offshore growth projects, which we expect will also allow Teekay Offshore to naturally delever its balance sheet... From a macro perspective, global deepwater oil production is expected to grow by approximately 25 percent by 2025.&rdquo;</li></ul><div class=\"tiny-share-widget\" data-id=\"3357684\" data-linked=\"Teekay -7% on wider than expected Q1 loss, warning on tanker rates\" data-tweet=\"$TK $TK $TNK - Teekay -7% on wider than expected Q1 loss, warning on tanker rates https://seekingalpha.com/news/3357684-teekayminus-7-on-wider-expected-q1-loss-warning-on-tanker-rates?source=tweet\" data-url=\"https://seekingalpha.com/news/3357684-teekayminus-7-on-wider-expected-q1-loss-warning-on-tanker-rates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>55&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357683\" data-ts=\"1526570409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPPI\" target=\"_blank\">SPPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357683-spectrum-pharma-up-17-on-late-stage-rolontis-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spectrum Pharma up 17% on late-stage Rolontis data</a></h4><ul><li>Spectrum Pharmaceuticals (<a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a> <font color='green'>+17%</font>) is up on slightly higher volume in apparent response to the <a href=\"https://seekingalpha.com/pr/17166352-correcting-replacing-spectrum-pharmaceuticals-announces-detailed-results-phase-3-study\" target=\"_blank\">release</a> of detailed results from its Phase 3 ADVANCE study comparing ROLONTIS (eflapegrastim) to Amgen's Neulasta (pegfilgrastim).</li><li>The study demonstrated the non-inferiority (no worse than) of ROLONTIS to Neulasta across all four treatment cycles. Also, there were no statistically significant differences across all secondary endpoints. The safety profiles were similar as well.</li><li>The company is currently conducting a second Phase 3, RECOVER, that should wind up later this year. A U.S. marketing application is on tap for Q4.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3327986-spectrum-pharmas-rolontis-par-neulasta-late-stage-study-shares-ahead-7-percent-premarket\" target=\"_blank\">Spectrum Pharma's Rolontis on par with Neulasta in late-stage study; shares ahead 7% premarket</a> (Feb. 5)</li><li>#ASCO18</li></ul><div class=\"tiny-share-widget\" data-id=\"3357683\" data-linked=\"Spectrum Pharma up 17% on late-stage Rolontis data\" data-tweet=\"$SPPI - Spectrum Pharma up 17% on late-stage Rolontis data https://seekingalpha.com/news/3357683-spectrum-pharma-up-17-on-late-stage-rolontis-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3357683-spectrum-pharma-up-17-on-late-stage-rolontis-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357678\" data-ts=\"1526569996\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CURO\" target=\"_blank\">CURO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357678-curo-announces-pricing-of-public-offering-of-common-stock\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CURO announces pricing of public offering of common stock</a></h4><ul>     <li>CURO Group (<a href='https://seekingalpha.com/symbol/CURO' title='CURO Group Holdings Corp.'>CURO</a> <font color='green'>+2.7%</font>) prices 5M shares of common stock by selling shareholders at $23.00/share.</li>     <li>CURO is not selling any shares and will not receive any proceeds from the sale of the shares offered by the selling stockholders in this offering.</li><li><a href=\"https://seekingalpha.com/pr/17166414-curo-announces-pricing-offering-common-stock-selling-stockholders\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3357678\" data-linked=\"CURO announces pricing of public offering of common stock\" data-tweet=\"$CURO - CURO announces pricing of public offering of common stock https://seekingalpha.com/news/3357678-curo-announces-pricing-of-public-offering-of-common-stock?source=tweet\" data-url=\"https://seekingalpha.com/news/3357678-curo-announces-pricing-of-public-offering-of-common-stock\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357676\" data-ts=\"1526569829\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTES\" target=\"_blank\">NTES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357676-neteaseminus-9_1-after-miss-analyst-caution-on-costs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NetEase -9.1% after miss, analyst caution on costs</a></h4><ul>   <li>NetEase (NASDAQ:<a href='https://seekingalpha.com/symbol/NTES' title='NetEase, Inc'>NTES</a>) is <font color='red'>9.1% lower</font> and at its lowest point since January 2017 after an <a href=\"https://seekingalpha.com/news/3357480-netease-minus-4_1-percent-forex-losses-spur-miss-earnings\" target=\"_blank\">earnings miss</a> exacerbated by foreign exchange and the prospect of ongoing rising costs.</li>    <li>Analysts are responding to the report with caution. Jefferies has slashed its price target to $276 from $310, pointing to an \"across the board\" increase in operating expenses in the miss. The company should be able to expand its addressable base of gamers with new genres, but that move could carry \"lower margin on higher marketing spend and lower average revenue per unit,\" the firm says. (h/t Bloomberg)</li>    <li>A smaller target reduction comes from Benchmark, which has reduced to $340 from $355. It's maintaining a Buy rating.</li>    <li>And Barclays reiterated its Hold stance with a price target of $280.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3357676\" data-linked=\"NetEase -9.1% after miss, analyst caution on costs\" data-tweet=\"$NTES - NetEase -9.1% after miss, analyst caution on costs https://seekingalpha.com/news/3357676-neteaseminus-9_1-after-miss-analyst-caution-on-costs?source=tweet\" data-url=\"https://seekingalpha.com/news/3357676-neteaseminus-9_1-after-miss-analyst-caution-on-costs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357672\" data-ts=\"1526569472\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNDX\" target=\"_blank\">SNDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357672-syndax-down-22-on-mid-stage-entinostat-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Syndax down 22% on mid-stage entinostat data</a></h4><ul><li>Thinly traded micro cap Syndax Pharmaceuticals (<a href='https://seekingalpha.com/symbol/SNDX' title='Syndax Pharmaceuticals, Inc.'>SNDX</a> <font color='red'>-21.9%</font>) slumps on more than double normal volume in apparent response to the <a href=\"https://seekingalpha.com/pr/17166626-syndax-announces-updated-results-phase-2-encore-601-trial-entinostat-combination-keytruda\" target=\"_blank\">release </a>of updated results from the ongoing Phase 2 <a href=\"https://clinicaltrials.gov/ct2/show/NCT02437136?spons=syndax&amp;phase=1&amp;rank=8\" target=\"_blank\">ENCORE 601</a> study assessing entinostat + Merck's Keytruda (pembrolizumab) across a range of cancers, including NSCLC, melanoma and microsatellite stable CRC.</li><li>The response rate was 11% (n=6/57) in NSCLC patients who had received prior treatment with a PD-1/L1 inhibitor + chemo. Median duration of response was 4.6 months.</li><li>The company says it has identified subgroup of NSCLC patients with elevated monocytes (type of white blood cell) that demonstrated a 29% response rate (n=4/14) and longer duration of response (progression-free survival = 5.4 months) compared to third-line chemo after PD-1&#40;L&#41;1 + platinum doublet therapy (2.8 months).&nbsp;It plans to launch a pivotal study in this patient population by year-end.</li><li>In the PD-1 treatment-experienced melanoma group, the combination produced an 18% confirmed response rate with a median duration of response of 9.1 months.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3311543-syndax-pharma-reports-study-results-support-treatment-benefit-entinostat-investors-unmoved\" target=\"_blank\">Syndax Pharma reports study results that support treatment benefit of entinostat,  investors unmoved after Nektar data, shares down 11%</a> (Nov. 13, 2017)</li><li>#ASCO18</li></ul><div class=\"tiny-share-widget\" data-id=\"3357672\" data-linked=\"Syndax down 22% on mid-stage entinostat data\" data-tweet=\"$SNDX - Syndax down 22% on mid-stage entinostat data https://seekingalpha.com/news/3357672-syndax-down-22-on-mid-stage-entinostat-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3357672-syndax-down-22-on-mid-stage-entinostat-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357674\" data-ts=\"1526569334\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVAV\" target=\"_blank\">AVAV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357674-aerovironment-hit-report-of-alleged-cover-up-of-illegal-activity\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AeroVironment hit by report of alleged cover-up of illegal activity</a></h4><ul>     <li>AeroVironment (<a href='https://seekingalpha.com/symbol/AVAV' title='AeroVironment, Inc.'>AVAV</a> <font color='red'>-1.1%</font>) moves lower in reaction to a <a href=\"http://www.aureliusvalue.com/research/aerovironment-ceos-alleged-cover-exposed/\" target=\"_blank\">negative report</a> from Aurelius Value, which says CEO Wahid Nawabi has \"orchestrated a cover-up of illegal activity and  dangerous conduct,\" citing allegations in an undisclosed whistleblower lawsuit.</li><li>According to the report, AVAV staffers allegedly transported live bombs on a commercial Delta Airlines flight in 2015, and the CEO pressured employees to mislead the government about ongoing security violations and mishandling of top-secret information.</li><li>AVAV shares trade at \"a  lofty valuation that anticipates significant future sales growth... But it  is our opinion that Anderson&rsquo;s whistleblower allegations introduce  material risks to the company&rsquo;s growth story.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3357674\" data-linked=\"AeroVironment hit by report of alleged cover-up of illegal activity\" data-tweet=\"$AVAV - AeroVironment hit by report of alleged cover-up of illegal activity https://seekingalpha.com/news/3357674-aerovironment-hit-report-of-alleged-cover-up-of-illegal-activity?source=tweet\" data-url=\"https://seekingalpha.com/news/3357674-aerovironment-hit-report-of-alleged-cover-up-of-illegal-activity\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357671\" data-ts=\"1526568851\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YY\" target=\"_blank\">YY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357671-yyplus-3_3-new-buy-rating-from-hua-tai\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">YY +3.3% with new Buy rating from Hua Tai</a></h4><ul>   <li>Shares in <a href='https://seekingalpha.com/symbol/YY' title='YY Inc.'>YY</a> are <font color='green'>up 3.3%</font> in Nasdaq trading after getting an initiation at Buy by Hua Tai Securities.</li>    <li>The firm set its price target at $126.50, implying 17% upside from current pricing. It joins nearly two dozen analysts who have Buy-equivalent ratings on the stock.</li>    <li>YY is <font color='red'>down 7.4%</font> YTD, but shares have nearly doubled (<font color='green'>up 94%</font>) over the past 12 months.</li>    <li>Earlier, the company announced the full exercise of the <a href=\"https://seekingalpha.com/news/3357548-yy-announces-full-exercise-allotment-option-huyas-ipo\" target=\"_blank\">over-allotment option</a> in the IPO of spin-off Huya; <a href='https://seekingalpha.com/symbol/HUYA' title='Huya Broadcasting'>HUYA</a> is now <font color='green'>up 4.5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3357671\" data-linked=\"YY +3.3% with new Buy rating from Hua Tai\" data-tweet=\"$YY $YY $HUYA - YY +3.3% with new Buy rating from Hua Tai https://seekingalpha.com/news/3357671-yyplus-3_3-new-buy-rating-from-hua-tai?source=tweet\" data-url=\"https://seekingalpha.com/news/3357671-yyplus-3_3-new-buy-rating-from-hua-tai\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357670\" data-ts=\"1526568547\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAXN\" target=\"_blank\">AAXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357670-axon-announces-pricing-of-public-offering-of-common-stock\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Axon announces pricing of public offering of common stock</a></h4><ul>     <li>Axon (<a href='https://seekingalpha.com/symbol/AAXN' title='Axon Enterprise, Inc.'>AAXN</a> <font color='green'>+4.8%</font>) prices underwritten public offering 4.3M shares at a price of $53.00/share.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3356487-axon-enterprises-launch-4m-share-offering\" target=\"_blank\">Axon Enterprises to launch 4M-share offering</a> (May 14)</li><li><a href=\"https://seekingalpha.com/pr/17166434-axon-announces-pricing-public-offering-common-stock\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3357670\" data-linked=\"Axon announces pricing of public offering of common stock\" data-tweet=\"$AAXN - Axon announces pricing of public offering of common stock https://seekingalpha.com/news/3357670-axon-announces-pricing-of-public-offering-of-common-stock?source=tweet\" data-url=\"https://seekingalpha.com/news/3357670-axon-announces-pricing-of-public-offering-of-common-stock\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357669\" data-ts=\"1526568260\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVP\" target=\"_blank\">AVP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357669-insider-buying-avon-products\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Insider buying at Avon Products</a></h4><ul> <li>Avon Products (NYSE:<a href='https://seekingalpha.com/symbol/AVP' title='Avon Products, Inc.'>AVP</a>) is&nbsp;<font color='green'>up 3.19%</font>&nbsp;with some insider buying activity in the background.</li> <li>The company discloses that CEO Jan Zijderveld picked up 250K shares at $1.93 and Global President Miguel Angel Fernandez Calero nabbed 100K shares at $1.89.</li><li>The insider buying comes with Avon trading just slightly above its multi-year low of $1.85.</li> <li><a href=\"https://seekingalpha.com/symbol/AVP/sec-filings\" target=\"_blank\">SEC Form 4s</a></li>  </ul><div class=\"tiny-share-widget\" data-id=\"3357669\" data-linked=\"Insider buying at Avon Products\" data-tweet=\"$AVP - Insider buying at Avon Products https://seekingalpha.com/news/3357669-insider-buying-avon-products?source=tweet\" data-url=\"https://seekingalpha.com/news/3357669-insider-buying-avon-products\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357644\" data-ts=\"1526567860\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DVAX\" target=\"_blank\">DVAX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357644-dynavax-down-13-on-sdminus-101-keytruda-melanoma-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dynavax down 13% on SD-101/Keytruda melanoma data</a></h4><ul><li>Dynavax (<a href='https://seekingalpha.com/symbol/DVAX' title='Dynavax Technologies Corporation'>DVAX</a> <font color='red'>-13.4%</font>)&nbsp;is down on increased volume in early trade in apparent response to the release of <a href=\"https://seekingalpha.com/pr/17166347-dynavax-present-new-data-sdminus-101-combination-keytruda-pembrolizumab-2018-american-society\" target=\"_blank\">updated results</a> from its ongoing <a href=\"https://seekingalpha.com/pr/17166347-dynavax-present-new-data-sdminus-101-combination-keytruda-pembrolizumab-2018-american-society\" target=\"_blank\">Phase 1/2 study</a> of SD-101 + Merck's Keytruda (pembrolizumab) in PD-1-naive advanced melanoma patients.</li><li>In 25 subjects, the overall response rate was 60% (n=15/25). Preliminary data presented last year at ASCO (seven patients) showed a 100% response rate.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3271405-combination-dynavaxs-sdminus-101-keytruda-show-100-percent-response-melanoma-study-shares\" target=\"_blank\">Combination of Dynavax's SD-101 and Keytruda show 100% response in melanoma study; shares ahead 4% after hours</a> (June 2, 2017)</li><li>#ASCO18</li></ul><div class=\"tiny-share-widget\" data-id=\"3357644\" data-linked=\"Dynavax down 13% on SD-101/Keytruda melanoma data\" data-tweet=\"$DVAX - Dynavax down 13% on SD-101/Keytruda melanoma data https://seekingalpha.com/news/3357644-dynavax-down-13-on-sdminus-101-keytruda-melanoma-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3357644-dynavax-down-13-on-sdminus-101-keytruda-melanoma-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>53&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357666\" data-ts=\"1526567822\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMBA\" target=\"_blank\">AMBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357666-ambarellaminus-5-possibly-on-mobileye-self-driving-vehicle-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ambarella -5% possibly on Mobileye self-driving vehicle deal</a></h4><ul><li>        Ambarella (NASDAQ:<a href='https://seekingalpha.com/symbol/AMBA' title='Ambarella'>AMBA</a>)&nbsp;<font color='red'>drops 5%</font>&nbsp;without a clear reason.</li><li>                  One possibility: Intel&rsquo;s Mobileye signed a deal with a European automaker to supply 8M cars with its advanced self-driving systems. Ambarella <a href=\"https://finance.yahoo.com/news/ambarella-demonstrates-fully-autonomous-vehicle-120000971.html\" target=\"_blank\">develops</a> vision processing chips for self-driving cars.&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3357495-big-self-driving-car-deal-mobileye\" target=\"_blank\">Big self-driving car deal for Mobileye</a> (May 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3357666\" data-linked=\"Ambarella -5% possibly on Mobileye self-driving vehicle deal\" data-tweet=\"$AMBA - Ambarella -5% possibly on Mobileye self-driving vehicle deal https://seekingalpha.com/news/3357666-ambarellaminus-5-possibly-on-mobileye-self-driving-vehicle-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3357666-ambarellaminus-5-possibly-on-mobileye-self-driving-vehicle-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357664\" data-ts=\"1526567412\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357664-eia-natural-gas-inventory\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EIA Natural Gas Inventory</a></h4><ul>     <li><a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory</a>: <strong>+106 Bcf</strong> vs. +105 Bcf consensus, +89 Bcf last week.</li><li>Futures&nbsp;<font color='red'>-0.67%</font>&nbsp;to $2.796.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a>,<a href='https://seekingalpha.com/symbol/DCNG' title='iPath Pure Beta Seasonal Natural Gas ETN'>DCNG</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3357664\" data-linked=\"EIA Natural Gas Inventory\" data-tweet=\"$UNG $DGAZ $UGAZ - EIA Natural Gas Inventory https://seekingalpha.com/news/3357664-eia-natural-gas-inventory?source=tweet\" data-url=\"https://seekingalpha.com/news/3357664-eia-natural-gas-inventory\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>78&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357653\" data-ts=\"1526566689\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VLO\" target=\"_blank\">VLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357653-valero-energy-spikes-5-on-morgan-stanley-upgrade-refining-optimism\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Valero Energy spikes 5% on Morgan Stanley upgrade, refining optimism</a></h4><ul>     <li>Valero Energy (<a href='https://seekingalpha.com/symbol/VLO' title='Valero Energy Corporation'>VLO</a> <font color='green'>+4.9%</font>) surges to a 52-week high Morgan Stanley <a href=\"https://thefly.com/thestreet/realmoney/index.php/VLO%3bMPCid2732926/VLO%3bMPC-Morgan-Stanley-upgrades-Valero-ahead-of-expected-golden-age-of-refining\" target=\"_blank\">upgrades shares to Overweight</a> from Equal Weight with a $140 price target, raised from $110, as the shift in global oil supply towards light oil and regulations to control  pollution should drive strong returns for complex refiners.</li><li>Stanley analyst Benny Wong says recent underinvestment in refining, reductions in capacity  additions and overstated concerns about long-term demand have set the stage for refining to enter a \"golden age\" through 2020.</li><li>Demand for jet fuel, mining, chemicals and heavy transport are \"here to stay\" while the world is falling short by about one refinery annually until 2020, Wong says.</li><li>Stanley considers VLO and  Marathon Petroleum (<a href='https://seekingalpha.com/symbol/MPC' title='Marathon Petroleum Corp.'>MPC</a> <font color='green'>+4.4%</font>) its top U.S. picks in the refining space; the firm raises its price target on MPC to $100 from $90.</li></ul><div class=\"tiny-share-widget\" data-id=\"3357653\" data-linked=\"Valero Energy spikes 5% on Morgan Stanley upgrade, refining optimism\" data-tweet=\"$VLO $VLO $MPC - Valero Energy spikes 5% on Morgan Stanley upgrade, refining optimism https://seekingalpha.com/news/3357653-valero-energy-spikes-5-on-morgan-stanley-upgrade-refining-optimism?source=tweet\" data-url=\"https://seekingalpha.com/news/3357653-valero-energy-spikes-5-on-morgan-stanley-upgrade-refining-optimism\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357648\" data-ts=\"1526566273\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KR\" target=\"_blank\">KR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357648-kroger-ocado-deal-shakes-up-online-grocery\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kroger-Ocado deal shakes up online grocery</a></h4><ul> <li>Investors and analysts are seeing a match made in grocery heaven after Kroger (NYSE:<a href='https://seekingalpha.com/symbol/KR' title='Kroger Co.'>KR</a>) announced a partnership with e-commerce specialist Ocado Group (<a href='https://seekingalpha.com/symbol/OCDGF' title='Ocado Group PLC'>OTCPK:OCDGF</a>, <a href='https://seekingalpha.com/symbol/OCDDY' title='Ocado Group PLC ADR'>OTC:OCDDY</a>).</li> <li>RBC Capital says the Kroger-Ocado partnership \"dwarfs\" the e-commerce efforts of other U.S. brick-and-mortar retailers due to the large fulfillment and distribution capabilities.</li> <li>The deal is also seen as a nice countermeasure by Kroger to Amazon's (<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a> <font color='red'>-0.1%</font>) grocery ambitions.</li><li>Today's development has significance for grocery chains Supervalu (<a href='https://seekingalpha.com/symbol/SVU' title='SUPERVALU Inc.'>SVU</a> <font color='green'>+1.2%</font>) and Sprouts Farmers Market (<a href='https://seekingalpha.com/symbol/SFM' title='Sprouts Farmers Market'>SFM</a> <font color='green'>+0.9%</font>), as well as Target (<a href='https://seekingalpha.com/symbol/TGT' title='Target Corporation'>TGT</a> <font color='green'>+0.9%</font>).</li><li>Shares of Kroger are <font color='green'>up 3.36%</font> in morning trading, while Ocado is <font color='green'>up 48%</font> in London. Bloomberg reports that Ocado is now a candidate to be included in the U.K.'s benchmark FTSE 100 index after the moonshot.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357527-kroger-partners-ocado\" target=\"_blank\">Kroger partners with Ocado</a> (May 17)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3357648\" data-linked=\"Kroger-Ocado deal shakes up online grocery\" data-tweet=\"$KR $KR $OCDGF - Kroger-Ocado deal shakes up online grocery https://seekingalpha.com/news/3357648-kroger-ocado-deal-shakes-up-online-grocery?source=tweet\" data-url=\"https://seekingalpha.com/news/3357648-kroger-ocado-deal-shakes-up-online-grocery\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357641\" data-ts=\"1526565860\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/USCR\" target=\"_blank\">USCR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357641-u-s-concreteminus-3-following-negative-spruce-point-tweet\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. Concrete -3% following negative Spruce Point tweet</a></h4><ul>     <li>U.S. Concrete (<a href='https://seekingalpha.com/symbol/USCR' title='US Concrete Inc.'>USCR</a> <font color='red'>-3.3%</font>) sinks in early trading after Spruce Point Capital releases a <a href=\"https://twitter.com/sprucepointcap/status/997109837363376128\" target=\"_blank\">Strong Sell recommendation</a> and points to a 60%-90% share price drop.</li>     <li>Spruce Point says USCR shares \"many similarities\" with two of the firm's other successful commodity shorts, Caesarstone and China Integrated Energy.</li>     <li>The firm believes it is time for \"significant change\" at USCR and calls for the immediate resignation of its CEO.</li></ul><div class=\"tiny-share-widget\" data-id=\"3357641\" data-linked=\"U.S. Concrete -3% following negative Spruce Point tweet\" data-tweet=\"$USCR - U.S. Concrete -3% following negative Spruce Point tweet https://seekingalpha.com/news/3357641-u-s-concreteminus-3-following-negative-spruce-point-tweet?source=tweet\" data-url=\"https://seekingalpha.com/news/3357641-u-s-concreteminus-3-following-negative-spruce-point-tweet\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357639\" data-ts=\"1526565834\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WFC\" target=\"_blank\">WFC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357639-wells-employees-altered-docs-wsj\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wells employees altered docs - WSJ</a></h4><ul><li><a href=\"https://www.wsj.com/articles/wells-fargo-employees-altered-information-on-business-customers-documents-1526564170?mod=e2tw&amp;tesla=y\" target=\"_blank\">via Emily Glazer at the <em>WSJ</em></a></li><li>Another cockroach appears at Wells Fargo (<a href='https://seekingalpha.com/symbol/WFC' title='Wells Fargo & Co.'>WFC</a> <font color='red'>-1.5%</font>), with the story alleging some employees in the business banking operation (known as the wholesale unit) as improperly altering customer information.</li><li>Previous issues at Wells have mostly been confined to the retail operation.</li><li>These actions apparently took place in 2017 and early this year as Wells was attempting to meet a deadline associated with a consent order over anti-money-laundering controls.</li><li>The bank found out recently, and then determined the behavior wasn't an isolated incident. It's since reported the issue to the OCC.</li></ul><div class=\"tiny-share-widget\" data-id=\"3357639\" data-linked=\"Wells employees altered docs - WSJ\" data-tweet=\"$WFC - Wells employees altered docs - WSJ https://seekingalpha.com/news/3357639-wells-employees-altered-docs-wsj?source=tweet\" data-url=\"https://seekingalpha.com/news/3357639-wells-employees-altered-docs-wsj\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357634\" data-ts=\"1526565423\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WWE\" target=\"_blank\">WWE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357634-wweplus-12_7-to-all-time-high-guggenheim-sees-tv-gold\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WWE +12.7% to all-time high as Guggenheim sees TV gold</a></h4><ul>   <li>World Wrestling Entertainment (NYSE:<a href='https://seekingalpha.com/symbol/WWE' title='World Wrestling Entertainment, Inc.'>WWE</a>) has <font color='green'>jumped 12.7%</font> and hit an all-time high after a note from Guggenheim suggests the company's TV rights renewals values are looking pretty conservative in the wake of reports of a new UFC deal.</li>    <li>The ultimate-fighting league reportedly has a deal with ESPN Plus for some $350M annual value on average.</li>    <li>That's a \"baseline minimum achievable target\" for WWE, says Guggenheim's Curry Baker, who points to the company's higher and more stable ratings than UFC along with a surplus of content hours. It means the renewal cycle could push WWE's annual average value above Guggenheim's estimate of $294M (and well above the company's current $145M). (h/t Bloomberg)</li>    <li>WWE is <font color='green'>up 42.5%</font> YTD and <font color='green'>up 123.5%</font> over the past 12 months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3357634\" data-linked=\"WWE +12.7% to all-time high as Guggenheim sees TV gold\" data-tweet=\"$WWE - WWE +12.7% to all-time high as Guggenheim sees TV gold https://seekingalpha.com/news/3357634-wweplus-12_7-to-all-time-high-guggenheim-sees-tv-gold?source=tweet\" data-url=\"https://seekingalpha.com/news/3357634-wweplus-12_7-to-all-time-high-guggenheim-sees-tv-gold\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357632\" data-ts=\"1526565331\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKTR\" target=\"_blank\">NKTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357632-nektar-down-9-on-release-of-phase-1-2-data-on-nktrminus-214\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nektar down 9% on release of Phase 1/2 data on NKTR-214</a></h4><ul><li>Nektar Therapeutics (<a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color='red'>-9%</font>) is down in light volume in early trade in response to the release of abstracts for ASCO that included updated data from the Phase 1/2 <a href=\"https://clinicaltrials.gov/ct2/show/NCT02983045?titles=pivot&amp;spons=nektar&amp;rank=1\" target=\"_blank\">PIVOT </a>study evaluating NKTR-214 + Bristol-Myers Squibb's Opdivo (nivolumab) in patients with advanced solid tumors.</li><li>Investors appear disappointed with the melanoma results. The overall response rate &#40;ORR&#41; in 23 patients was 52% (n=12/23) while the disease control rate &#40;DCR&#41;&nbsp;(responders + those with stable cancer) was 78% (n=18/23). The ORR for Opdivo alone in the <a href=\"https://clinicaltrials.gov/ct2/show/NCT01721772?titles=checkmate-066&amp;spons=bristol&amp;rank=1\" target=\"_blank\">CHECKMATE-066</a> study (BRAF V600 wild-type) was 34% while the DCR was 82%.</li><li>#ASCO18</li></ul><div class=\"tiny-share-widget\" data-id=\"3357632\" data-linked=\"Nektar down 9% on release of Phase 1/2 data on NKTR-214\" data-tweet=\"$NKTR - Nektar down 9% on release of Phase 1/2 data on NKTR-214 https://seekingalpha.com/news/3357632-nektar-down-9-on-release-of-phase-1-2-data-on-nktrminus-214?source=tweet\" data-url=\"https://seekingalpha.com/news/3357632-nektar-down-9-on-release-of-phase-1-2-data-on-nktrminus-214\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357616\" data-ts=\"1526563742\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATUS\" target=\"_blank\">ATUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357616-altice-usaplus-1_8-keybanc-starts-overweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Altice USA +1.8% as KeyBanc starts at Overweight</a></h4><ul>    <li>Altice USA (NYSE:<a href='https://seekingalpha.com/symbol/ATUS' title='Altice USA'>ATUS</a>) is <font color='green'>up 1.8%</font> premarket after an initiation at Overweight by KeyBanc.</li>    <li>The firm set its price target at $25, implying 24% upside.</li>    <li>Shares are <font color='red'>down 4.7%</font> YTD; at $20.23, they're still below last summer's $30 IPO price.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3357616\" data-linked=\"Altice USA +1.8% as KeyBanc starts at Overweight\" data-tweet=\"$ATUS - Altice USA +1.8% as KeyBanc starts at Overweight https://seekingalpha.com/news/3357616-altice-usaplus-1_8-keybanc-starts-overweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3357616-altice-usaplus-1_8-keybanc-starts-overweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357612\" data-ts=\"1526563288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HPE\" target=\"_blank\">HPE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357612-otr-global-upgrades-hewlett-packard-enterprise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OTR Global upgrades Hewlett Packard Enterprise</a></h4><ul><li>           OTR Global upgrades Hewlett Packard Enterprise (NYSE:<a href='https://seekingalpha.com/symbol/HPE' title='Hewlett Packard Enterprise'>HPE</a>) from Mixed to Positive. </li><li> Source: Briefing.com. </li><li> HPE shares are&nbsp;<font color='green'>up 0.6%</font>&nbsp;premarket to $17.73.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3357612\" data-linked=\"OTR Global upgrades Hewlett Packard Enterprise\" data-tweet=\"$HPE - OTR Global upgrades Hewlett Packard Enterprise https://seekingalpha.com/news/3357612-otr-global-upgrades-hewlett-packard-enterprise?source=tweet\" data-url=\"https://seekingalpha.com/news/3357612-otr-global-upgrades-hewlett-packard-enterprise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357611\" data-ts=\"1526563183\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLNK\" target=\"_blank\">BLNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357611-premarket-gainers-of-9-05-5-17-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (5/17/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/BLNK' title='Blink Charging Co.'>BLNK</a> <font color='green'>+16%</font>.</li><li><a href='https://seekingalpha.com/symbol/NERV' title='Minerva Neurosciences'>NERV</a>&nbsp;<font color='green'>+13%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3357601-minerva-neurosciences-roluperidone-shows-treatment-effect-schizophrenia-patients-shares-ahead\" target=\"_blank\">announcing</a> roluperidone effective in treatment of schizophrenia patients.</li><li><a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a>&nbsp;<font color='green'>+13%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3357560-loxos-ret-candidate-loxominus-292-shows-treatment-effect-early-stage-study-still-lags\" target=\"_blank\">announcing</a> details of LOXO-292 clinical data presentations at the 2018 ASCO Annual Meeting.</li><li><a href='https://seekingalpha.com/symbol/WWE' title='World Wrestling Entertainment, Inc.'>WWE</a> <font color='green'>+11%</font>.</li><li><a href='https://seekingalpha.com/symbol/IMMU' title='Immunomedics, Inc.'>IMMU</a>&nbsp;<font color='green'>+9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3357603-immunomedics-lead-adc-shows-positive-action-subgroup-treatment-resistant-breast-cancer\" target=\"_blank\">announcing</a> data of sacituzumab govitecan in estrogen receptor-positive breast cancer.</li><li><a href='https://seekingalpha.com/symbol/BDSI' title='BioDelivery Sciences International, Inc.'>BDSI</a>&nbsp;<font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3357593-biodelivery-sciences-prices-convertible-stock-offering-shares-ahead-18-percent-premarket\" target=\"_blank\">pricing</a> convertible stock offering.</li><li><a href='https://seekingalpha.com/symbol/IHT' title='Innsuites Hospitality Trust'>IHT</a> <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/symbol/CHEK' title='Check-Cap Ltd.'>CHEK</a>&nbsp;<font color='green'>+6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3357535-check-cap-beats-0_41\" target=\"_blank\">Q1 earnings</a>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3357611\" data-linked=\"Premarket Gainers as of 9:05 am (5/17/2018)\" data-tweet=\"$BLNK $BLNK $NERV - Premarket Gainers as of 9:05 am (5/17/2018) https://seekingalpha.com/news/3357611-premarket-gainers-of-9-05-5-17-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3357611-premarket-gainers-of-9-05-5-17-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357608\" data-ts=\"1526562945\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MLNX\" target=\"_blank\">MLNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357608-mellanox-techplus-5_2-on-raised-q2-fy-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mellanox Tech +5.2% on raised Q2, FY guidance</a></h4><ul><li>        Mellanox Tech (NASDAQ:<a href='https://seekingalpha.com/symbol/MLNX' title='Mellanox Technologies, Ltd.'>MLNX</a>) <a href=\"https://seekingalpha.com/pr/17166866-mellanox-technologies-increases-second-quarter-full-year-2018-outlook\" target=\"_blank\">updates</a> its Q2 and FY18 outlook.</li><li>               Q2 guidance now has revenue from $260M to $270M (was: $255M to $265M).&nbsp;</li><li>               FY18 has revenue of $1.05B to $1.07B (was: $1.03B to $1.05B) and non-GAAP operating margin of 23% to 24% (was: 21% to 22%).&nbsp;</li><li>               Mellanox shares are&nbsp;<font color='green'>up 5.2%</font>&nbsp;premarket to $89.35.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3357608\" data-linked=\"Mellanox Tech +5.2% on raised Q2, FY guidance\" data-tweet=\"$MLNX - Mellanox Tech +5.2% on raised Q2, FY guidance https://seekingalpha.com/news/3357608-mellanox-techplus-5_2-on-raised-q2-fy-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3357608-mellanox-techplus-5_2-on-raised-q2-fy-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357601\" data-ts=\"1526562767\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NERV\" target=\"_blank\">NERV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357601-minerva-neurosciences-roluperidone-shows-treatment-effect-in-schizophrenia-patients-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Minerva Neurosciences&#39; roluperidone shows treatment effect in schizophrenia patients; shares ahead 13% premarket</a></h4><ul> <li>Minerva Neurosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/NERV' title='Minerva Neurosciences'>NERV</a>) <a href=\"https://seekingalpha.com/pr/17166705-journal-clinical-psychiatry-publishes-positive-results-cognitive-performance-phase-2b-trial\" target=\"_blank\">announces</a> that The Journal of Clinical Psychiatry has published online results demonstrating cognitive improvements in patients with schizophrenia treated with roluperidone (MIN-101). The results also demonstrated that cognitive improvements correlate with previously reported improvements in negative symptoms.</li>     <li>Roluperidone is a novel compound with affinities for 5HT<sub>2A</sub> and sigma<sub>2</sub> receptors and no direct binding to dopamine receptors.</li>    <li>Previously announced results from this trial, published in the American Journal of Psychiatry, showed that roluperidone achieved its primary outcome in the trial, demonstrating statistically significant superiority over placebo in improving negative symptoms in schizophrenia patients.</li><li>Shares are up&nbsp;<font color='green'>13%</font>&nbsp;premarket.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3357601\" data-linked=\"Minerva Neurosciences&#39; roluperidone shows treatment effect in schizophrenia patients; shares ahead 13% premarket\" data-tweet=\"$NERV - Minerva Neurosciences&#39; roluperidone shows treatment effect in schizophrenia patients; shares ahead 13% premarket https://seekingalpha.com/news/3357601-minerva-neurosciences-roluperidone-shows-treatment-effect-in-schizophrenia-patients-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3357601-minerva-neurosciences-roluperidone-shows-treatment-effect-in-schizophrenia-patients-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357606\" data-ts=\"1526562618\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JNCE\" target=\"_blank\">JNCE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357606-premarket-losers-of-9-05-5-17-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am (5/17/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/JNCE' title='Jounce Therapeutics'>JNCE</a>&nbsp;<font color='red'>-33%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3357539-jounce-32-percent-premarket-announcement-trial-data-lead-candidate-jtxminus-2011\" target=\"_blank\">announcement</a> of trial data on lead candidate JTX-2011.</li><li><a href='https://seekingalpha.com/symbol/JCP' title='J.C. Penney Company Inc.'>JCP</a>&nbsp;<font color='red'>-12%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3357553-j-c-penney-misses-0_02-beats-revenue\" target=\"_blank\">Q1 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/ACXM' title='LiveRamp Holdings, Inc.'>ACXM</a>&nbsp;<font color='red'>-8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3357420-acxiom-beats-0_06-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/NTES' title='NetEase, Inc'>NTES</a>&nbsp;<font color='red'>-8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3357484-netease-misses-0_36-beats-revenue\" target=\"_blank\">Q1 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/AYR' title='Aircastle Limited'>AYR</a> <font color='red'>-7%</font>.</li><li><a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color='red'>-7%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3357606\" data-linked=\"Premarket Losers as of 9:05 am (5/17/2018)\" data-tweet=\"$JNCE $JNCE $JCP - Premarket Losers as of 9:05 am (5/17/2018) https://seekingalpha.com/news/3357606-premarket-losers-of-9-05-5-17-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3357606-premarket-losers-of-9-05-5-17-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357603\" data-ts=\"1526562349\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMU\" target=\"_blank\">IMMU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357603-immunomedics-lead-adc-shows-positive-action-in-subgroup-of-treatment-resistant-breast-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immunomedics&#39; lead ADC shows positive action in subgroup of treatment-resistant breast cancer patients; shares up 8% premarket</a></h4><ul><li>Immunomedics (NASDAQ:<a href='https://seekingalpha.com/symbol/IMMU' title='Immunomedics, Inc.'>IMMU</a>) is up&nbsp;<font color='green'>8%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/17166322-immunomedics-announces-promising-data-sacituzumab-govitecan-estrogen-receptor-positive\" target=\"_blank\">release of data</a> on antibody-drug conjugate IMMU-132 (sacituzumab govitecan) in heavily pretreated patients with ER+/HER2- metastatic breast cancer. The results will be presented at ASCO in Chicago.</li><li>The overall response rate was 31% and the clinical benefit rate (responders + those with stable cancer) was 48%.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316711-immunomedics-immuminus-132-shows-31-percent-response-rate-tnbc-shares-ahead-19-percent\" target=\"_blank\">Immunomedics' IMMU-132 shows 31% response rate in TNBC; shares ahead 19%</a> (Dec. 6, 2017)</li><li>#ASCO18</li></ul><div class=\"tiny-share-widget\" data-id=\"3357603\" data-linked=\"Immunomedics&#39; lead ADC shows positive action in subgroup of treatment-resistant breast cancer patients; shares up 8% premarket\" data-tweet=\"$IMMU - Immunomedics&#39; lead ADC shows positive action in subgroup of treatment-resistant breast cancer patients; shares up 8% premarket https://seekingalpha.com/news/3357603-immunomedics-lead-adc-shows-positive-action-in-subgroup-of-treatment-resistant-breast-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3357603-immunomedics-lead-adc-shows-positive-action-in-subgroup-of-treatment-resistant-breast-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357593\" data-ts=\"1526561506\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BDSI\" target=\"_blank\">BDSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357593-biodelivery-sciences-prices-convertible-stock-offering-shares-ahead-18-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioDelivery Sciences prices convertible stock offering; shares ahead 18% premarket</a></h4><ul><li>Thinly traded micro cap BioDelivery Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/BDSI' title='BioDelivery Sciences International, Inc.'>BDSI</a>) is up&nbsp;<font color='green'>18%</font>&nbsp;premarket on average volume in response to the <a href=\"https://seekingalpha.com/pr/17166805-biodelivery-sciences-announces-pricing-50-million-equity-financing\" target=\"_blank\">pricing </a>for its $50M direct offering of Series B Non-Voting Convertible Preferred Stock to institutional investors.</li><li>Each Series B share will be sold at $10K each and will be convertible into common shares at $1.80 (~5,556 shares).</li><li>Closing date is May 21.</li><li>Yesterday's close was $1.80.</li></ul><div class=\"tiny-share-widget\" data-id=\"3357593\" data-linked=\"BioDelivery Sciences prices convertible stock offering; shares ahead 18% premarket\" data-tweet=\"$BDSI - BioDelivery Sciences prices convertible stock offering; shares ahead 18% premarket https://seekingalpha.com/news/3357593-biodelivery-sciences-prices-convertible-stock-offering-shares-ahead-18-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3357593-biodelivery-sciences-prices-convertible-stock-offering-shares-ahead-18-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357590\" data-ts=\"1526561096\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LUV\" target=\"_blank\">LUV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357590-southwest-airlines-completes-engine-fan-blade-inspections\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Southwest Airlines completes engine fan blade inspections</a></h4><ul> <li>Southwest Airlines (NYSE:<a href='https://seekingalpha.com/symbol/LUV' title='Southwest Airlines Co.'>LUV</a>) says it has completed a round of engine <a href=\"https://www.cnbc.com/2018/05/17/stocks-making-the-biggest-moves-premarket-wmt-csco-f-ko-cmcsa-jack-more.html?__source=newsletter|breakingnews\" target=\"_blank\">inspections</a> across its fleet.</li> <li>CEO Gary Kelly confirms that small number of engine fan blades were sent back to the manufacturer for more testing out of an abundance of caution. The fan blades were not sent back due to metal fatigue.</li><li>Shares of Southwest are <font color='green'>up 0.66%</font> premarket to $53.36. LUV is -19.01% YTD.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3357590\" data-linked=\"Southwest Airlines completes engine fan blade inspections\" data-tweet=\"$LUV - Southwest Airlines completes engine fan blade inspections https://seekingalpha.com/news/3357590-southwest-airlines-completes-engine-fan-blade-inspections?source=tweet\" data-url=\"https://seekingalpha.com/news/3357590-southwest-airlines-completes-engine-fan-blade-inspections\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357589\" data-ts=\"1526560891\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALGN\" target=\"_blank\">ALGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357589-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Align Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/ALGN' title='Align Technology, Inc.'>ALGN</a>) initiated with Outperform rating and $340 (18% upside) price target at Evercore ISI.</li><li>Helius Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/HSDT' title='Helius Medical Technologies, Inc.'>HSDT</a>) initiated with Buy rating and $14 (26% upside) price target at BTIG Research.</li><li>Baxter International (NYSE:<a href='https://seekingalpha.com/symbol/BAX' title='Baxter International Inc'>BAX</a>) resumed with Overweight rating and $77 (9% upside) price target at Piper Jaffray.</li><li>Jounce Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/JNCE' title='Jounce Therapeutics'>JNCE</a>) downgraded to Market Perform with a $13 (26% downside risk from yesterday's close) price target at Well Fargo following underwhelming JTX-2011 data. Shares are down&nbsp;<font color='red'>34%</font>&nbsp;premarket on increased volume.</li><li>Loxo Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a>) price target raised to $190 (36% upside) from $145 at Stifel following its release of LOXO-292 data. Shares are up&nbsp;<font color='green'>14%</font>&nbsp;premarket on modest volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3357589\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$ALGN $ALGN $HSDT - Premarket analyst action - healthcare https://seekingalpha.com/news/3357589-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3357589-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357586\" data-ts=\"1526560504\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COST\" target=\"_blank\">COST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357586-costco-flirts-200-amid-wall-street-love\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Costco flirts with $200 amid Wall Street love</a></h4><ul> <li>Loop Capital initiates coverage on Costco (NASDAQ:<a href='https://seekingalpha.com/symbol/COST' title='Costco Wholesale Corporation'>COST</a>) with a Buy rating.</li> <li>The investment firm assigns a price target of $224 on the retailer to rep 13% upside potential for shares.</li><li>There are now 22 Buy equivalent recommendations from Wall Street analysts on the books vs. 8 Hold equivalents and no Sells, per Bloomberg.</li> <li>COST <font color='green'>+0.42%</font> premarket to $199.55 vs. a 52-week trading range of $150.00 to $199.88.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3357586\" data-linked=\"Costco flirts with $200 amid Wall Street love\" data-tweet=\"$COST - Costco flirts with $200 amid Wall Street love https://seekingalpha.com/news/3357586-costco-flirts-200-amid-wall-street-love?source=tweet\" data-url=\"https://seekingalpha.com/news/3357586-costco-flirts-200-amid-wall-street-love\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357580\" data-ts=\"1526560243\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ECYT\" target=\"_blank\">ECYT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357580-endocytes-radiotherapeutic-177lu-psmaminus-617-shows-positive-effect-in-mid-stage-prostate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Endocyte&#39;s radiotherapeutic 177Lu-PSMA-617 shows positive effect in mid-stage prostate cancer study; shares ahead 2% premarket</a></h4><ul><li>Endocyte (NASDAQ:<a href='https://seekingalpha.com/symbol/ECYT' title='Endocyte, Inc.'>ECYT</a>) is up&nbsp;<font color='green'>2%</font>&nbsp;premarket, albeit on only 99 shares, in response to its <a href=\"https://seekingalpha.com/pr/17166374-endocyte-announces-presentation-phase-2-data-investigator-initiated-prostate-cancer-trial\" target=\"_blank\">announcement</a> of updated data from its Phase 2 trial of&nbsp;<sup>177</sup>Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC). The results will be presented at ASCO in Chicago.</li><li>In 50 treated patients, 62% (n=31) experienced greater than a 50% reduction in PSA (prostate-specific antigen) levels while 44% (n=22) experienced at least an 80% reduction in PSA. Median overall survival was 13.5 months for the first cohort of 30 patients.</li><li><sup>177</sup>Lu-PSMA-617, licensed from ABX GmbH, selectively delivers short-range beta-emitting radioactive isotope lutetium to tumor cells that express prostate-specific membrane antigen &#40;PSMA&#41;.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3334191-endocyte-readies-late-stage-study-lu-psmaminus-617-prostate-cancer-shares-7-percent\" target=\"_blank\">Endocyte readies late-stage study of Lu-PSMA-617 in prostate cancer; shares up 7%</a> (Feb. 26)</li><li>#ASCO18</li></ul><div class=\"tiny-share-widget\" data-id=\"3357580\" data-linked=\"Endocyte&#39;s radiotherapeutic 177Lu-PSMA-617 shows positive effect in mid-stage prostate cancer study; shares ahead 2% premarket\" data-tweet=\"$ECYT - Endocyte&#39;s radiotherapeutic 177Lu-PSMA-617 shows positive effect in mid-stage prostate cancer study; shares ahead 2% premarket https://seekingalpha.com/news/3357580-endocytes-radiotherapeutic-177lu-psmaminus-617-shows-positive-effect-in-mid-stage-prostate?source=tweet\" data-url=\"https://seekingalpha.com/news/3357580-endocytes-radiotherapeutic-177lu-psmaminus-617-shows-positive-effect-in-mid-stage-prostate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:30 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357579\" data-ts=\"1526559737\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DDS\" target=\"_blank\">DDS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357579-dillards-tracks-higher-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dillard&#39;s tracks higher after earnings</a></h4><ul> <li>Dillard's (NYSE:<a href='https://seekingalpha.com/symbol/DDS' title='Dillard&#39;s Inc.'>DDS</a>) reports a 2% increase in total merchandise sales and comparable sales during <a href=\"https://seekingalpha.com/pr/17166685-dillard-s-inc-reports-first-quarter-results\" target=\"_blank\">Q1</a>.</li> <li>Strength in home and furniture, ladies' accessories and lingerie and juniors' and children's apparel helped to offset some weakness in men's apparel and shoes.</li> <li>The company says gross margin from retail operations fell 66 bps, compared to a year ago. SG&amp;A expenses were down 10 bps to 27.9% of sales.</li> <li>\"Our positive sales momentum continued into the first quarter. We believe this indicates our customer is more comfortable spending in this economic environment, and we hope the positive trend continues,\" says Dillard's CEO&nbsp; William Dillard.</li> <li>DDS <font color='green'>+1.56%</font> premarket to $73.12.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357549-dillards-beats-0_12-beats-revenue\" target=\"_blank\">Dillard's beats by $0.12, beats on revenue</a> (May 17)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3357579\" data-linked=\"Dillard&#39;s tracks higher after earnings\" data-tweet=\"$DDS - Dillard&#39;s tracks higher after earnings https://seekingalpha.com/news/3357579-dillards-tracks-higher-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3357579-dillards-tracks-higher-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357575\" data-ts=\"1526559324\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NXPI\" target=\"_blank\">NXPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357575-nxp-semiconductorsplus-1_5-after-china-approves-toshiba-chip-unit-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NXP Semiconductors +1.5% after China approves Toshiba chip unit sale</a></h4><ul><li>NXP Semiconductors (NASDAQ:<a href='https://seekingalpha.com/symbol/NXPI' title='NXP Semiconductors'>NXPI</a>)&nbsp;<font color='green'>gains 1.5%</font>&nbsp;premarket following news that China antitrust regulators approved the sale of Toshiba&rsquo;s chip unit to a US-led consortium.</li><li>Investors hope the Toshiba move means China will approve Qualcomm&rsquo;s (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>) acquisition of NXP.</li><li>Qualcomm shares are&nbsp;<font color='green'>up 0.14%</font>&nbsp;premarket to $56.78.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357515-china-approves-toshiba-chip-unit-sale\" target=\"_blank\">China approves Toshiba chip unit sale</a> (May 17)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3356847-reuters-outward-change-chinas-review-qualcomm-nxp-deal\" target=\"_blank\">Reuters: No outward change to China's review of Qualcomm, NXP deal</a> (May 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3357575\" data-linked=\"NXP Semiconductors +1.5% after China approves Toshiba chip unit sale\" data-tweet=\"$NXPI $NXPI $QCOM - NXP Semiconductors +1.5% after China approves Toshiba chip unit sale https://seekingalpha.com/news/3357575-nxp-semiconductorsplus-1_5-after-china-approves-toshiba-chip-unit-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3357575-nxp-semiconductorsplus-1_5-after-china-approves-toshiba-chip-unit-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}